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Human cathepsin A (also known as Protective Protein/Cathepsin A, PPCA; E.C. 
3.4.16.5) is a lysosomal serine carboxypeptidase. Cathepsin A is also involved in a 
complex with two other lysosomal enzymes: lysosomal neuraminidase (NEU1, E.C. 
3.2.1.18) and β-galactosidase (GLB1, E.C. 3.2.1.23). Deficiency in cathepsin A and 
NEU1 result in the lysosomal storage diseases, galactosialidosis and sialidosis 
respectively. Deficiency in GLB1 results in GM1 gangliosidosis and Morquio B diseases.  
Cathepsin A protease activity is spatially regulated by activation of the inactive 
precursor form to the mature form in the lysosome. Structural studies on the mature form 
of cathepsin A were performed to understand the mechanism of activation. We present 
X-ray crystallographic, mass spectrometric, amino acid sequencing, and enzymatic data 
to support a cleavage-only model, involving proteolytic processing of the precursor with 
no conformational change required. Additionally we show that multiple cleavage sites on 
the surface of the protein ensure activation of cathepsin A in the lysosome. The 
structural results presented here point to new avenues for the design of mechanism-
based inhibitors of the enzyme. 
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NEU1 is an exosialidase that cleaves terminal sialic acids from glycoproteins and 
glycolipids in the lysosome and on the cell surface highlighting its importance in cellular 
functions such as signal transduction and cancer metastasis pathways. NEU1 activity is 
deficient in sialidosis and galactosialidosis, and there are no available treatments for 
both the diseases. Although the molecular basis for sialidosis and galactosialidosis is not 
fully understood, complex formation is proposed to be important for the activity and 
stability of NEU1. In the current study we show that cathepsin A directly interacts with 
NEU1 and this interaction is not required for the catalytic activity of NEU1, instead 
facilitates stabilization of NEU1. The data presented here provide new insight into the 
NEU1-cathepsin A complex. We further present a proof-of-concept study for 
pharmacological chaperone therapy using inhibitors targeting NEU1 for the treatment of 
sialidosis and galactosialidosis. 
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1        CHAPTER 1  
INTRODUCTION 
1.1 Lysosomal multi-enzyme complex 
Lysosomal storage diseases are inherited metabolic diseases caused by 
mutations in a single gene, encoding a hydrolase, receptor, transporter or transferase, 
involved in lysosomal function [1, 2]. Genetic mutations lead to deficiency in activity of 
the corresponding protein, resulting in lysosomal dysfunction and ultimately a storage 
disease. There are more than 50 lysosomal storage diseases reported, with a collective 
incidence of 1 in ~7700 [3, 4]. The rate of occurrence varies for different diseases, and 
varies in specific populations for each disease. While the metabolic bases for these 
diseases are known, the biochemical and cellular effects of the deficiencies in the 
lysosomal proteins are not understood in most of the diseases [1]. 
A multi-enzyme complex is proposed to exist in the lysosome, composed of at 
least three proteins: cathepsin A (CATA), β-galactosidase (GLB1) and neuraminidase 1 
(NEU1). NEU1 is an exo-α-sialidase, deficiency in which causes sialidosis, and GLB1 is 
the lysosomal β-galactosidase, deficiency in which causes GM1 gangliosidosis or 
Morquio B diseases. The combined deficiency in both NEU1 and GLB1 in some patients 
with clinical manifestations similar to sialidosis or GM1 gangliosidosis, led to the proposal 
of a NEU1-GLB1 complex mediated by cathepsin A. Cathepsin A, also referred to as 
Protective Protein/Cathepsin A (PPCA) is encoded by the CTSA gene, mutation of which 
causes galactosialidosis. A fourth enzyme, N-acetyl-galactosamine-6-sulfate sulfatase 
(GALNS) was later shown to be associated with the complex [5]. In this section, 
properties of cathepsin A, lysosomal neuraminidase and β-galactosidase, and their 
associated diseases will be discussed, followed by a report on the biochemical 
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characterization of the CATA-GLB1-NEU1 and CATA-NEU1 complexes reported in 
literature.  
1.1.1 Structure and function of human cathepsin A 
1.1.1.1 Cathepsin A and Galactosialidosis 
Cathepsin A is a ubiquitously expressed [6] multifunctional enzyme with distinct 
properties, resulting in its involvement in various cellular processes. Cathepsin A exhibits 
enzymatic activity as a serine carboxypeptidase in the acidic pH of the lysosome [7, 8] 
and also has deamidase and esterase activity at neutral pH [9, 10]. Cathepsin A was 
shown to play a role in chaperone-mediated autophagy by regulating degradation of the 
receptor LAMP2 [11]. It acts on multiple peptide hormones, including endothelin-1 and 
angiotensin I, highlighting its importance in endocrine regulation [12, 13]. Additionally, 
cathepsin A is a major hydrolase for converting peptidic pro-drugs to active compounds 
[14]. In addition to its enzymatic function, cathepsin A functions as a structural 
component of a multi-enzyme complex present in the lysosome and on the cell 
membrane [15]. Cathepsin A forms a complex with lysosomal neuraminidase (NEU1) 
and β-galactosidase (GLB1), and the complex is disrupted in the cells of patients with 
galactosialidosis [9, 16, 17]. Elastin Binding Protein (EBP), a non-enzymatic splice 
variant of GLB1, replaces GLB1 in the complex expressed on the cell membrane [18, 
19]. Stability and activity analyses of NEU1 and GLB1 in galactosialidosis fibroblasts 
showed reduction in the half-lives and activities of these enzymes independent of 
cathepsin A activity [7, 20, 21]. 
Galactosialidosis is an autosomal recessive disease, requiring two altered alleles 
of the gene to exhibit clinical manifestations. Galactosialidosis presents as early infantile, 
 3	  
late infantile and juvenile/adult types based on severity and age of onset of clinical 
manifestations, with early onset being the most severe. In general, all galactosialidosis 
patients present with coarse facies, cherry-red spots, vertebral changes, and foam cells 
in bone marrow. Additional symptoms include fetal hydrops, kidney failure, cardiac 
involvement and neuronal involvement including myoclonus, cerebellar ataxia and 
mental retardation. In lysosomal storage diseases, deficiency in enzyme activity results 
in accumulation of substrates, which can be detected in cells and urine. In all reported 
cases of galactosialidosis, N-glycosidic oligosaccharides with terminal sialic acids 
(neuraminic acid) are detected in fibroblasts and urine, similar to mutations in NEU1 that 
lead to sialidosis. No significant levels of oligosaccharides with terminal β-galactose 
sugars are detected, suggesting presence of adequate amount of residual β-
galactosidase activity in galactosialidosis patients. The similarity in the substrates 
accumulated and in the disease phenotypes between galactosialidosis and sialidosis 
suggests that many of the galactosialidosis disease manifestations can be attributed to 
loss of neuraminidase activity. To date the contribution, if any, of the enzymatic activity 
of cathepsin A or β-galactosidase in galactosialidosis disease pathogenesis is not fully 
understood. Diagnosis can be confirmed by testing for β-galactosidase and 
neuraminidase activities in white blood cells or cultured fibroblasts and genetic analysis 
by DNA sequencing of the three relevant genes. 
Mutations in the CTSA gene lead to structural and functional alterations in 
cathepsin A resulting in galactosialidosis. To date a total of 26 mutations (including 
missense/nonsense, splicing, deletions and insertions) have been reported in the 
literature. Of these, 17 are missense mutations resulting in single amino-acid 
substitutions in the protein, and involve alterations to residues causing debilitating effects  
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Table 1.1: Cathepsin A mutations causing galactosialidosis 
 
No. Mutation protein Effect on cathepsin A Phenotype Reference 
1. Q21R Affect structure EI [22] 
2. S23Y Affect structure EI [23] 
3. W37R Affect structure EI [22] 
4. G57S Affect nucleophile (Ser) EI [24] 
5. G57V Affect nucleophile (Ser) EI [25] 
6. S62L Affect structure EI [26] 
7. H70R Affect structure EI [27] 
8. V104M Affect structure EI [23] 
9. L208P Affect structure EI [23] 
10. C213R Abolish disulphide bond EI [27] 
11. Y221N Affect structure LI [23] 
12. Y367C Affect structure EI [22] 
13. M378T Disrupt dimerization EI/LI [23] 
14. R396W Potentially affect structure LI [25] 
15. G411S Disrupt dimerization EI [23] 
16. F412V Disrupt dimerization LI [28] 
17. K425E Disrupt dimerization J/A [29] 
Legend: EI Early infantile, LI Late infantile, J/A Juvenile/adult 
 
 
 
on the structure of cathepsin A (Table 1.1). Given that cathepsin A is a component of a 
lysosomal multi-enzyme complex, and galactosialidosis disease manifestation is similar 
to sialidosis (a deficiency of associated neuraminidase-1), it is surprising to note that 
only two of these missense mutations are on the surface of the protein.  
Currently there are no approved treatments for patients with galactosialidosis, 
merely symptomatic treatment. Enzyme replacement therapy (ERT), which involves 
repeated infusions of recombinant protein, was tested using insect-cell expressed 
cathepsin A in galactosialidosis fibroblasts [30] and in a mouse model [31]. Although 
clearance of accumulated substrate was observed in several cell types, occurrence of 
fatal immune reactions in mice to the recombinant protein underscores the complexities 
associated with ERT application [31]. Gene therapy using adeno-associated virus (AAV)-
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based vectors for expression of cathepsin A showed better results with fewer 
complications in the mouse model of galactosialidosis [32]. 
1.1.1.2 Structure of precursor PPCA 
The structure of insect cell expressed precursor form of human cathepsin A was 
solved by x-ray crystallography in 1995 [33]. Although the product of the CTSA gene is 
named cathepsin A, the protein has no appreciable sequence identity with other cellular 
cathepsins. The yeast (CPD-Y) and wheat (CPD-WII) serine carboxypeptidases are the 
closest homologs of cathepsin A, with sequence identity of 31% and 38% respectively. 
The crystal structure of precursor cathepsin A was solved by molecular replacement 
using the CPD-WII structure as a model [33]. 
Cathepsin A is a 452 amino acid, 54 kDa glycoprotein, after signal sequence 
cleavage and addition of two N-linked glycosylations per monomer. The crystal structure 
of precursor cathepsin A dimer showed each monomer with two domains, the core 
domain (1-182 and 303-452) interrupted by a cap domain insertion (183-302) [33]. The 
cap domain is further divided into a helical subdomain (183-253) important for 
dimerization and a mixed three-stranded β-sheet maturation subdomain (254-302) [28]. 
The core domain has a α/β hydrolase fold containing the active site, as in CPW and 
CPY, while the structures differ in the cap domain, resulting in altered substrate 
specificity (Figure 1.1a, b).  
Cathepsin A undergoes proteolytic processing in the lysosome to form the 
mature protease, with removal of a 2kDa peptide (termed excision peptide) resulting in a 
large (32 kDa) and a small (20 kDa) subunit, covalently linked by two disulfide bonds 
[34]. The excision peptide was originally specified as residues 285-298, based on the 
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Figure 1.1: Structural of precursor cathepsin A 
 (a) Structural comparison of monomers of cathepsin A (green), carboxypeptidase Y 
(CPY, grey) and wheat carboxypeptidase (CPW, pale yellow) show a similar core 
domain structure with differences in the cap domain. (b) Primary structure of precursor 
cathepsin A (green) showing the position of the N-linked glycans, blocking peptide (dark 
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blue), excision peptide (yellow), and connecting sequence (cyan). Disulfide bonds are 
depicted as brackets. (c) Each monomer of cathepsin A is composed of a core hydrolase 
domain containing the catalytic residues (spheres) and the cap domain. In the precursor, 
the active site is occluded by the blocking peptide.  
 
identification of Met299 as the first residue of the small subunit (by N-terminal 
sequencing) [35] and presence of Arg284 in tryptic peptides of mature cathepsin A 
purified from placental tissue [36].  
The catalytic triad in cathepsin A consists of Ser150, His429 and Asp372, 
positioned in a catalytically competent arrangement at the base of the substrate-binding 
pocket (Figure 1.1c). However, in the precursor structure, the inactivation of the enzyme 
occurs via occlusion of the substrate-binding pocket by two segments of the maturation 
subdomain, described as the blocking peptide (272-277) and the excision peptide (285-
298). Consequently, a two-step mechanism of activation involving cleavage of the 
excision peptide followed by conformational changes in the blocking peptide and 
adjacent segment (in the maturation subunit) was proposed (Figure 1.1c). This proposed 
mechanism of activation was a novel mechanism not seen in any of the other proteases. 
1.1.2 NEU1 and sialidosis 
Neuraminidases (also referred to as sialidases) are enzymes that cleave 
neuraminic acids (also known as sialic acids) present on glycoproteins, oligosaccharides 
and gangliosides. There are more than forty known sialic acids in nature, composed of a 
nine-carbon pyranose ring with either N-acetyl group (Neu5Ac) or N-glycolyl group 
(Neu5Gc) at C5. Further heterogeneity in sialic acids arises from modifications of the 
hydroxyl groups by methylation, acylation, phosphorylation and sulfation [37]. Sialic 
acids are involved in many cellular and molecular processes, typically occurring on the 
non-reducing termini of oligosaccharides present on proteins, lipids and cell surfaces. 
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They are linked to other sugars (including galactose, N-acetylgalactosamine or N-
acetylglucosamine) via the hydroxyl at the C2 position, making a glycosidic bond 
cleavable by neuraminidases. Neuraminidases are expressed in diverse organisms 
including viruses, bacteria, and eukaryotes. In humans, four types of neuraminidases 
exist differing in substrate specificity and cellular localization: lysosomal (NEU1), 
cytosolic (NEU2), plasma membrane (NEU3) and lysosomal or mitochondrial membrane 
(NEU4). NEU1, NEU2 and NEU4 cleave sialic acids on oligosaccharides, glycoproteins 
and gangliosides, whereas NEU3 cleaves sialic acids only on gangliosides. Changes in 
activity or expression of NEU2, NEU3 or NEU4 are not reported to be associated with 
disease.  
NEU1 (EC: 3.2.1.18) is an exo-α-sialidase localized to the lysosome and the cell 
membrane, where it cleaves α(2-3) and α(2-6) linked sialic acids on glycoproteins 
(Figure 1.2). It is a 43 kDa polypeptide, after cleavage of the 47 amino-acid signal 
sequence from the N-terminus and addition of N-linked glycosylations. Based on 
similarity to other bacterial and human neuraminidases, NEU1 is hypothesized to have a 
β-propeller fold. Unlike the other human neuraminidases, NEU1 is expressed 
ubiquitously in all tissue types tested [38]. In the lysosome NEU1 begins the catabolism 
of oligopeptides and oligosaccharides by cleaving the terminal sialic acid, which is 
followed by cleavage of the remaining sugars in a sequential manner by other enzymes. 
In addition to its catabolic function in the lysosome, NEU1 has been shown to be 
involved in regulation of exocytosis by desialylation of LAMP-1 [39]. NEU1 is expressed 
on the plasma membrane as part of a complex with cathepsin A and elastin binding 
protein where it functions in a variety of cellular processes including elastogenesis [40, 
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41], cell adhesion [42], phagocytosis [43], proliferation [44], and has been proposed as a 
potential target for suppression of cancer cell survival and metastasis [45].  
Mutations in the NEU1 gene lead to defective NEU1 protein and cause 
accumulation of sialyl-glycoconjugates in cells and tissues, leading to sialidosis. 
Depending on age of onset and apparent physical changes, sialidosis is classified as 
type I and II. Type I is a milder form of the disease, presenting symptoms in the second 
to third decade of life. No physical changes are seen in these patients (normosomatic), 
and early symptoms include changes in visual acuity and ocular cherry-red spots with 
progressive generalized myoclonus. Patients with physical changes are grouped under 
type II sialidosis (dismorphic), and are characterized by somatic changes and early 
onset of disease symptoms, which progress rapidly. Clinical manifestations, which 
progressively worsen include hydrops fetalis, visceromegaly, dysostosis multiplex and 
mental retardation. In all cases of sialidosis, oligopeptides and oligosaccharides were 
observed with α(2-3) and α(2-6) neuraminic acids at the non-reducing end and N-
acetylgalactosamine at the reducing end. Biochemical detection of sialyl-
oligosaccharides in fibroblasts or body fluids (urine and amniotic fluid), complementation 
tests and deficiency in neuraminidase activity can be used for diagnosis of sialidosis. 
There are no approved treatments for sialidosis, although enzyme replacement therapy 
and gene therapy are being investigated in mouse models of sialidosis [46].  
1.1.3 β-galactosidase and GM1 gangliosidosis and Morquio B 
Human β-galactosidase (GLB1, EC 3.2.1.23), the product of the GLB1 gene 
cleaves β-linked galactose sugars from different substrates (Figure 1.3). GLB1 is 
synthesized as an 88 kDa glycoprotein, after signal sequence cleavage and addition of 
N-linked glycosylations (7 potential sites). The structure of human GLB1 was solved by 
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Figure 1.2: Reaction catalyzed by neuraminidase 
Terminal neuraminic acid on a glycoconjugate (R) is cleaved to form neuraminic acid. 
 
 
 
 
Figure 1.3: Substrates of β-galactosidase 
(a) GM1 ganglioside consists of five sugar molecules linked to a ceramide. The terminal 
β-linked galactose sugar is cleaved (red arrrow). (b) Keratan sulfate is composed of a 
disaccharide galactose and N-acetylglucosamine repeat. The C6 position is sulfated 
differentially.  
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x-ray crystallography and was shown to be a dimer with each monomer composed of 
three domains, a TIM barrel containing the active site, β-domain 1 and β-domain 2 [47]. 
GLB1 has been shown to undergo proteolytic processing in the lysosome to form 64 kDa 
and 20 kDa subunits that remain bound [47, 48], although the specific sites of cleavage 
are not known.  
GLB1 cleaves β-linked galactose on GM1 and GA1 gangliosides, lactosylceramide, 
asialofetuin, keratan sulfate and galactose-containing oligosaccharides and 
oligopeptides in the lysosome (reviewed in [49]). GM1 ganglioside, composed of an 
oligosaccharide chain linked to a hydrophobic ceramide (Figure 1.3a), are present on 
cell membranes where they are involved in diverse functions. Due to the hydrophobic 
nature of the sphingolipids, β-galactosidase depends on an activator protein (saposin B) 
for activity against lipid substrates [50, 51]. Deficiency in β-galactosidase activity due to 
mutations in the GLB1 gene results in two lysosomal storage diseases with different 
disease manifestations. Although the structure of GLB1 and the type of substrates 
accumulated are known, it is not understood how GLB1 mutations present as either GM1 
gangliosidosis or Morquio B, dissimilar diseases affecting different organ systems.  
GM1 gangliosidosis is a neurodegenerative disease with visceral involvement, 
classified as infantile (type I), late infantile/juvenile (type II) and adult (type III) based on 
age of onset, with heterogenous phenotypic manifestations. Symptoms include 
neurodegeneration, joint contractures, gait and speech abnormalities, severe dystonia 
and mild skeletal changes. In contrast, Morquio B is a disease of the skeletal system, 
with lower incidence compared to GM1 gangliosidosis [47]. Substrates accumulated in 
Morquio B disease are mainly keratan sulfate, in agreement with lack of neuronal 
symptoms. Keratan sulfate is a high molecular weight mucopolysaccharide consisting of 
a repeating disaccharide unit of β-linked galactose and β-linked N-acetylglucosamine 
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(which may be sulfated at C6 position) (Figure 1.3b). Early development is normal in 
patients with Morquio B but is followed by growth retardation and progression of physical 
deformities. Symptoms include stiffness in motor movements, dwarfism, swelling of distal 
ends of long bones, spinal deformities and genu valgum (knock-knees). Biochemical 
analysis of storage compounds is used for diagnosis of GM1 gangliosidosis and Morquio 
B diseases, along with analysis of β-galactosidase activity in fibroblasts, leukocytes and 
tissues. Diagnosis can be confirmed by genetic analysis of the GLB1 gene.  
1.1.4 Characterization of the CATA-GLB1-NEU1 complex 
As mentioned above, a multi-enzyme complex involving NEU1 and GLB1 was 
proposed based on biochemical and phenotypic analyses in patients presenting a 
sialidosis-like disease. The normal phenotype could be restored in patient fibroblasts by 
the addition of NH4Cl-treated lysates of normal fibroblasts [52], suggesting the presence 
of at least one interacting protein. Cathepsin A was identified as a component of the 
complex by N-terminal sequencing of proteins co-purified with GLB1. The complex was 
detected in multiple cell types, suggesting a ubiquitous expression pattern similar to the 
individual proteins [9]. 
To understand the molecular bases of galactosialidosis and determine the 
composition of the proteins involved, the complex was isolated and purified from tissue 
homogenates. The complex was isolated using a carbohydrate-binding concavalin A 
affinity column, followed by chromatography on para-aminophenyl-thiogalactose-C-
sepharose resin (with affinity for GLB1) or agarose-Phe-Leu column (with affinity for 
cathepsin A). Density gradient techniques were used to analyze the molecular mass of 
the complex and individual proteins, which were identified further by SDS-PGE and 
activity assays. A ~600 kDa complex exhibiting GLB1, NEU1 and cathepsin A activities 
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was reported with the complex purified by affinity against GLB1 [53, 54]. However, a 
1.27 MDa in dynamic equilibrium with a 680 kDa and 98 kDa species was shown with 
the complex purified by affinity towards cathepsin A [55]. Based on the activity profile of 
the peaks, a 680 kDa species was proposed to be a GLB1-cathepsin A core complex, 
which interacts with NEU1 to form the 1.27 MDa complex. In each of the methods, NEU1 
activity was always observed in the high molecular weight fraction. Immunoprecipitation 
(IP) and metabolic labeling studies with heterogeneously expressed proteins using anti-
GLB1, anti-cathepsin A and anti-NEU1 antibodies provided further evidence of a NEU1-
cathepsin A-GLB1 complex, however, no report of a direct interaction between the 
protein has been reported to date. Heterogeneously expressed human GLB1, NEU1 and 
cathepsin A did not form a high molecular weight complex, as observed with protein 
purified from tissue samples. GLB1 and cathepsin A have also been observed to exist in 
free active dimeric forms, and multiple oligomeric forms of NEU1 have been reported. 
Taken together, the disparate biochemical results raise the possibility of a dynamic 
equilibrium in the association of the lysosomal enzymes.  
1.1.5 Elastin binding receptor 
Elastin-binding protein (EBP) coded by the GLB1 gene is a naturally occurring 
splice variant of lysosomal β-galactosidase, and is localized to the cell membrane. EBP 
acts as a chaperone and binds to tropoelastin and delivers it to the cell surface, 
preventing the premature aggregation of tropoelastin. EBP is also plays an important 
role in the elastic fiber assembly process [56]. Elastic fiber abnormalities are observed in 
patients with GLB1 gene mutations, highlighting the importance of EBP in elastogenesis. 
EBP is expressed on the cell membrane as part of a multi-protein complex. NEU1 and 
cathepsin A (previously known to be associated with the cell membrane) were identified 
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as components of the complex with EBP, and together the complex was termed the 
elastic receptor complex. Further, it was shown that NEU1 and cathepsin A activity in the 
receptor complex was required for many cellular processes including elastic fiber 
assembly, signal transduction and interaction with mitogenic growth factors PDGF-BB 
and IGF-2. 
1.1.6 NEU1-cathepsin A dimer complex 
The complete loss in NEU1 function observed in cathepsin A deficient cells 
(unlike in GLB1 deficient cells), highlights the importance of the NEU1-cathepsin A 
interaction. However, due to the many contradictory observations reported in the 
literature, many aspects of the complex remain unclear. A 1:1 ratio of active NEU1 and 
cathepsin A monomers was proposed for the two-protein complex by sedimentation 
velocity analysis with insect cell purified proteins [57]. Prevention of NEU1 
oligomerization by interaction with cathepsin A was proposed to be required for 
expression of NEU1 activity, contradicting earlier reports of active NEU1 in a 680 kDa 
and a 1.27 MDa complex with β-gal and cathepsin A in acidic pH. The existence of a 
two-protein complex mediated by direct NEU1-cathepsin A interaction has not been 
reported. 
Cathepsin A is proposed to activate and stabilize NEU1 in cells, since no NEU1 
activity is observed in cathepsin A deficient cells. However, the activation mechanism is 
not known. An increase in affinity for substrate of activated NEU1 compared to pre-
activated NEU1 suggested conformational changes in NEU1. This mechanism of 
activation was investigated further, showing a two-fold increase in NEU1 activity (above 
basal activity) on incubation with 8-fold excess of cathepsin, although the kinetic 
parameters were not investigated. The specific activity of the activated NEU1 reported in 
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this study is 1000-fold less than reported values for other neuraminidases (NEU2 and 
NEU3), which brings to question if the measured activity is reflective of in vivo activity or 
does NEU1 have comparable activity to the rest of the family members. 
Most lysosomal enzymes are trafficked to the lysosome via the mannose-6-
phosphate receptor, a mechanism involving interaction of the receptor in the Golgi with 
phosphorylated mannose sugars on the lysosomal protein. NEU1 has two N-linked 
glycosylations per monomer that have low levels of phosphorylation, resulting in 
inefficient lysosomal trafficking. Co-transfection of wild type (but not a transport deficient 
mutant) cathepsin A suppressed the trafficking defect of NEU1, suggesting the NEU1-
cathepsin A complex is formed in the ER and is required for lysosomal trafficking of 
NEU1 [16]. However, lysosomal localization of NEU1 was observed when expressed in 
normal and cathepsin A deficient fibroblasts from a galactosialidosis patient, but was 
degraded rapidly in the lysosome in the absence of cathepsin A. The C-terminal 
internalization signal YGTL (YXXΦ motif, where X can be any amino acid and Φ is a 
hydrophobic amino acid) on NEU1 was shown to mediate intracellular distribution of 
NEU1, lending support to an alternate pathway for NEU1 trafficking, although the 
alternate receptor has not yet been reported. 
 
Although the genetic bases of lysosomal storage diseases are known, the 
genotype to phenotype relation is not completely understood even in the most studied 
diseases. As mentioned earlier, cathepsin A is prominent modulator of vascular 
homeostasis and NEU1 is important in cellular pathways such as signal transduction, 
protein half-life, and cancer metastasis. Knowledge of the molecular properties and 
interactions of these proteins will facilitate a better understanding of their function in 
cellular processes in diseased and normal conditions. Despite the three-decade-old 
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proposal for the existence of the lysosomal complex, many aspects of the cathepsin A-
NEU1-GLB1 complex are not clearly understood. Most importantly, it is not clear if and 
how the proteins interact to form the complex, whether the complex forms in the ER or in 
the lysosome and how complex formation affects their function. Cathepsin A, NEU1 and 
GLB1 are activated in the lysosome, however the mechanisms of activation are not 
clearly understood (Figure 1.4). Through the work presented in this thesis we aim to gain 
insight into the properties and function of the enzymes involved in the multi-enzyme 
complex and apply that to explore developing treatment strategies. 
 
 
 
 
 
 
Figure 1.4: Analysis of the current status of the NEU1-cathepsin A complex  
The conflicting hypotheses from previous reported studies of the two-protein complex 
and properties of the complex still not clearly understood are denoted by question marks. 
Does the complex form in the ER and is it required for the stability of NEU1 and CATA? 
Once in the lysosome it is not clear if the activity of NEU1 depends on complex formation 
or if it is required for stability. NEU1 exhibits neuraminidase activity on the cell surface, 
however since the optimum pH if 4.5, it is not clear how it catalyzes substrates in the 
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neutral environment of the extracellular matrix. There are conflicting reports for the 
trafficking of NEU1, whether it depends on cathepsin A for trafficking or it interacts with 
receptors of an alternate pathway
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2      CHAPTER 2  
PROTEOLYTIC PROCESSING OF HUMAN CATHEPSIN A 
Kolli, N. and Garman, S. (2014) J. Biol. Chem. Papers In Press 
2.1 Introduction  
Cathepsin A functions in various pathways as a significant component of the 
lysosomal multi-enzyme complex, and in cellular functions as an enzyme due to its 
peptidase, deamidase and esterase activities [7-14, 16, 17, 21]. Inhibitors against 
cathepsin A are currently in Phase I clinical trials for hypertension due to its central role 
in vasoregulation [58, 59]. Understanding the structure and function of the catalytically 
active mature protease is thus important in understanding its cellular regulation, and in 
the design and optimization of inhibitors specific to cathepsin A.  
Most known carboxypeptidases belong to serine carboxypeptidase and metallo-
carboxypeptidase protein families, and cathepsin A belongs to the S10 family of serine 
proteases along with yeast (CPY) and wheat carboxypeptidases (CPW) [33]. Although 
carboxypeptidases across families to not have high structural similarity, they are 
composed of a core domain with α/β-hydrolase fold containing the catalytic residues, 
and a cap domain with variation in size and shape (Figure 1.1a) [60, 61]. The cap 
domains occur as insertions in the core domain (CPY, CPW, cathepsin A) or at the N-
terminus (M14 family of metalloproteases), and function in the formation of the substrate 
recognizing pockets (CPY), in blocking the active site from solvent (CPW, cathepsin A) 
and in dimerization (cathepsin A). Cap domains involved in blocking the active site are 
either cleaved off (CPW, cathepsin A, M14family metallocarboxypeptidases) or undergo 
conformational changes allowing accessibility to the active site (lipases) [60, 61]. 
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Although cathepsin A shares high structural and functional similarity with CPY 
and CPW, a novel mechanism of activation was proposed based on the structure of 
precursor cathepsin A. Activation of cathepsin A was proposed to occur in a two-step 
process involving cleavage of the 1.6 kDa excision peptide, followed by conformational 
changes in the blocking peptide of the maturation subdomain, allowing substrate access 
to the active site. However, the maturation subdomain (254-302) of precursor 
cathepsin A has multiple surface-exposed potential cleavage sites similar to the 
originally proposed sites (Arg284, Arg292, Arg298), lending support to the possibility of 
activation by proteolytic removal of a larger segment without conformational changes. To 
date, the long-standing question of the activation mechanism of human cathepsin A 
remains unclear.  
Here we report the crystal structure of mature and catalytically active 
cathepsin A, suggesting an alternate model for activation of cathepsin A. Using X-ray 
crystallography, mass spectrometry, and amino-acid sequencing, we show activation of 
precursor cathepsin A by proteolytic removal of a larger 3.3 kDa peptide that includes 
the blocking peptide, bypassing the requirement for conformational changes. Our results 
suggest an activation mechanism of cathepsin A consistent with homologous 
carboxypeptidases such as CPW. In addition, we show the importance of removal of the 
blocking peptide on carboxypeptidase activity of human cathepsin A, using a N-blocked 
dipeptide carbobenzoxycarbonyl-phenylalanine-leucine (Z-Phe-Leu) as substrate. The 
structure and enzymatic studies presented here clarify the regulatory mechanisms of 
cathepsin A and suggest new mechanisms for the control of the cathepsin A in 
therapeutic uses. 
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2.2 Experimental strategy 
The proteolytic processing of the inactive precursor leads to formation of mature 
cathepsin A. In this study we determined the structure of the mature form of cathepsin A 
by X-ray crystallography. The residues removed during the activation were identified by 
mass spectrometry and N-terminal sequencing of the various forms of cathepsin A. To 
gain more insights into the importance of removal of the blocking peptide, 
carboxypeptidase activity of cathepsin A as a function of its proteolytic processing was 
performed. Activation by cleavage at alternate cleavage sites in the maturation sub-
domain was analyzed by analyzing alanine-scanning mutant expression in mammalian 
cells. 
2.3 Results 
2.3.1 The precursor and mature structures of cathepsin A superimpose, without 
need for a conformational change  
To understand the activation of PPCA by conversion of precursor to mature protease, we 
determined the structure of recombinant insect-cell expressed mature cathepsin A by X-
ray crystallography to 2.8Å resolution (Figure 2.1d, Table 4.1). The structure of mature 
PPCA superimposes with the previously reported structure of precursor cathepsin A, 
with a root mean square deviation (rmsd) of 0.55Å for all Cα atoms. The core domains 
(1-182 and 303-452) of mature and precursor cathepsin A superimpose with an rmsd of 
0.28Å on 332 Cα atoms. The cap domains (183-302) of precursor and mature cathepsin 
A also superimpose well, with an rmsd of 0.32Å, indicating no substantial conformational 
changes take place after maturation. As in the precursor cathepsin A structure, each 
monomer of the dimeric protease has four disulfide bonds and two N-linked  
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Table 4.1: Crystallographic data 
 
 
 Native 1 Native 2 
PDB code 4MWS 4MWT 
Beamline APS 24-ID-C APS 24-ID-C 
Wavelength, Å 0.9792 0.9792 
Space Group P3121 
[52:48 twin] 
P3121 
a and c cell lengths, Å 134.9, 99.9 134.6, 99.8 
Resolution, Å* 50-2.8 (2.85-2.8) 50-3.85 (3.92-3.85) 
Observations* 142,222 (6,536) 33,205 (1,694) 
Unique observations* 25,989 (1,257) 9,724 (404) 
Completeness* 99.0 (98.0) 95.2 (98.0) 
Multiplicity* 5.5 (5.2) 3.5 (3.4) 
Rsym, %* 14.9 (88.4) 17.5 (52.7) 
<I/σI>* 15.7 (1.7) 5.9 (1.8) 
   
Rwork/Rfree, % 14.7 / 19.5 32.3 / 32.5 
Atoms 6755 6677 
  Protein 6602 6596 
  Carbohydrate 137 81 
  Water 4 0 
  Other 34 0 
Average B-factor (Å2) 58 81 
  Protein 67 81 
  Carbohydrate 87 154 
  Water 40 - 
Ramachandran plot, %   
  Favored 95.5 95.7 
  Allowed 4.2 3.9 
  Outlier 0.4 0.4 
RMS deviations   
  Bonds, Å 0.008 0.008 
  Angles, ° 1.16 1.15 
 
*Highest resolution shell appears in parentheses 
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Figure 2.1: Structural comparison of precursor and mature cathepsin A reveal no 
large conformational changes 
Structure of mature cathepsin A (purple) dimer superimposes on the precursor 
cathepsin A (green) without conformational changes. Removal of the blocking peptide, 
excision peptide, and connecting sequence in the mature protease renders the active 
site accessible for substrate binding (surface representation). In the inset, 2Fo-Fc density 
from a σA-weighted map contoured at 1σ shows the 253-303 disulfide that flanks the 
region processed during maturation. 
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Figure 2.2: The catalytic and substrate binding residues in the structure of mature 
cathepsin A are competent for catalysis  
The substrate-binding residues are matched to those of wheat carboxypeptidase 
complex with benzylsuccinic acid (PDB 1WHS). (a) Superposition of precursor (green) 
and mature cathepsin A (purple) structures show no conformational changes in the 
terminal carboxylate binding site (blue), S1΄ binding site (orange), the S1 binding site 
(cyan) of the mature protease or the residues adjoining the conserved disulfide bond 
(C253-C303) proximal to the cleavage sites. (b) No conformational changes are 
observed in the structure of mature cathepsin A for these residues on inhibitor binding 
(light brown, PDB 4AZ0). (c and d) Superimposition of yeast (grey) and wheat (pale 
green) carboxypeptidases on mature cathepsin A (purple) shows conservation of the 
substrate binding and catalytic residues across these homologous proteins. The disulfide 
bond corresponding to C253-C303 in cathepsin A is conserved among the three 
proteases. Wheat carboxypeptidase undergoes cleavage at the region adjoining the 
disulfide bond without any conformational change, similar to mature cathepsin A.  
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carbohydrates per monomer (Asn117 and Asn305). The carbohydrate at Asn117 
participates in a crystal contact, making crystallization difficult.  
As expected for an active mature cathepsin A, electron density for the excision 
peptide (285 to 297) is not observed in the structure of mature cathepsin A. However, a 
much larger region (259 to 297, including the putative blocking peptide 272-277) is 
missing from the electron density, suggesting that the excision peptide might be larger 
than previously hypothesized (Figure 2.1d), or disordered crystallographically. In the 
structure of mature cathepsin A, the absence of the blocking and excision peptides 
results in a completely solvent accessible substrate-binding pocket. No significant 
conformational changes are observed in the residues involved in catalysis or substrate 
binding between the precursor and mature forms (Figure 2.2). The precursor and mature 
forms of human cathepsin A can each be superimposed on those of its homolog CPY 
(precursor cathepsin A to CPY 0.40 Å rmsd; mature cathepsin A to CPY 0.51Å rmsd for 
all Cα atoms) and CPW (precursor cathepsin A to CPW 0.85Å rmsd; mature cathepsin A 
to CPW 0.55Å rmsd for all Cα atoms). 
2.3.2 The excision peptide is larger than 1.6 kDa  
The crystal structure of mature cathepsin A suggested that the number of 
residues removed during maturation might be larger than the previously proposed 13 
residues (285-298, 1.6 kDa). To test this possibility, we subjected cathepsin A to SDS-
PAGE and mass spectrometry analysis at different stages in the maturation process 
(Figure 2.3). Reducing SDS-PAGE analysis of cathepsin A shows the processing of the 
single chain precursor polypeptide into the two-chain mature form as a function of time. 
MALDI mass spectrometry of cathepsin A revealed changes in mass as the protein 
matured. The MALDI spectrum of purified cathepsin A showed primarily a 54.4 kDa 
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protein for the zymogen (single chain) and a 51.1 kDa protein (large plus small subunits 
bound by disulfide bonds) at complete maturation, with a mixture of the two during 
intermediate stages. The difference in the masses of the precursor and mature cathepsin 
A samples in the mass spectrometer reveal the size of the peptide removed during 
processing is 3.3 ± 0.2 kDa (Figure 2.3).  
2.3.3 The precursor is cleaved at Ser293 to form the small subunit of the mature 
protease 
Proteolytic processing of precursor cathepsin A into mature cathepsin A 
produces a new N-terminal residue in the small subunit. To identify the precise 
proteolytic location during maturation, the small subunit of mature cathepsin A was N-
terminally sequenced by Edman degradation. The sequencing unambiguously identifies 
Ser293 as the first residue of the small subunit (shown in Figure 2.4a). Because the 
mass spectrometry shows the excision peptide is 3.3 kDa and the first residue of the 
small subunit is Ser293, we estimate that the other cleavage reaction occurs after 
Arg262 or Lys265 (Figure 2.4a). Removal of the 263-292 or 266-292 peptide would 
result in a mass reduction of 3.6 kDa or 3.2 kDa respectively, within the error estimate of 
the mass spectrometry measurement on the glycoprotein (3.3 ± 0.2 kDa). 
Arg292 immediately precedes Ser293, suggesting processing by a trypsin-like 
protease. In contrast, Arg298 (which had been previously proposed to be removed 
during maturation) [33] is clearly seen in the electron density maps of mature 
cathepsin A. Leupeptin reduced the proteolytic processing of cathepsin A (Figure 2.5), 
consistent with processing by a trypsin-like protease. In an effort to suppress cleavage of 
the 1.6 kDa excision peptide, we expressed and purified a cathepsin A double mutant  
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Figure 2.3: The excision peptide is 3.3 kDa 
(a) Reducing SDS-PAGE shows full-length precursor cathepsin A (lane 2) undergoing 
proteolytic cleavage to form large and small subunits of the mature cathepsin A (lane 4), 
through a processing intermediate (lane 3). (b) MALDI spectra of cathepsin A forms 
(lanes 2-4 from the SDS gel) during maturation. Sample one (top panel) is predominantly 
54.4 kDa precursor with a small concentration of 51.1 kDa mature cathepsin A. The 
middle panel shows similar amounts of full-length and processed cathepsin A, giving rise 
to two peaks in the spectrum. The completely processed cathepsin A (bottom panel) 
shows a single peak at 51.1 kDa. Arrows point to zoomed insets of each peak. The 
mass measurements of the glycoprotein are accurate to 1-2 amino acids (scale bar 
indicates 0.1 kDa).  
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Figure 2.4: The blocking peptide is removed during maturation 
(a) Electron density is absent for the 259-297 sequence (grey) in mature cathepsin A 
(purple) but appears in the precursor structure (green). N-terminal sequencing of the 
mature cathepsin A small subunit and MALDI analysis suggest two potential excision 
peptides (yellow), option 1 (266-292, 3.2 kDa) and option 2 (266-292, 3.6 kDa). The 
molecular weight of the excision peptide originally proposed in 1995 (1.6 kDa, yellow) is 
inconsistent with mass spectrometric and amino-acid sequencing of the small subunit of 
mature cathepsin A. (b) and (c) Cathepsin A can be activated by cleavage at multiple 
cleavage sites. (b) Suppressing cleavage at the sites predicted in (a) by expressing and 
purifying Arg to Ala point mutants of cathepsin A (R262A/R292A and 
R284A/R298A/S150A) also generates mature cathepsin A, suggesting processing at 
alternative sites. The triple and double mutants undergo cleavage of the precursor to 
form mature large and mature small subunits. Lanes 1-3 are 12% acrylamide, and lane 4 
is 10%. (c) Immunoprecipitation (IP) of different mutants (suppression of cleavage sites 
corresponding to those present on either side of the blocking peptide in the originally 
predicted excision peptide, R284A/R298A/S150A) and nucleophile knock out (S150A) 
background) in HEK293T cells with anti-FLAG antibody also results in cleavage of the 
precursor to mature large and mature small, presumably by cleavage at alternate sites. 
Anti-cathepsin A western blot (top panel) of IP samples show bands corresponding to 
precursor and mature large cathepsin A. Anti-FLAG western blot (bottom panel) of 
respective cell lysates show bands corresponding to the small subunit of cathepsin A.  
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Figure 2.5: Inhibition of proteolytic processing of cathepsin A 
The proteolytic processing of insect cell expressed cathepsin A by endogenous insect 
cell proteases was partially inhibited only in the presence of Leupeptin (lane 6). Other 
inhibitors did not affect the processing, seen by the presence of a mature large and small 
subunit (lanes 3 - 5), when compared to the full-length precursor form (lane 2).  
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R262A/R292A, which also undergoes processing to form large and small subunits, 
suggesting alternate avenues for the maturation of cathepsin A. 
Additionally, to suppress cleavage of the predicted 1.6 kDa excision peptide, we 
generated a triple mutant form of cathepsin A, changing the two previously proposed 
cleavage sites (Arg284 and Arg298) and the catalytic nucleophile (Ser150) to alanine. 
The cathepsin A triple mutant S150A/R284A/R298A also undergoes cleavage into large 
and small subunits, comparable to the wild-type cathepsin A (Figure 2.4b), suggesting 
these sites are not mandatory for the activation of cathepsin A. 
To examine maturation of cathepsin A in human cells, we expressed recombinant 
human cathepsin A constructs in HEK293T cells. Cathepsin A expressed in human cells 
mimicked that expressed in insect cells, undergoing processing into large and small 
subunits. We replaced Arg and Lys residues in the processing region (on either side of 
the blocking peptide) with Alas, and the resulting proteins were analyzed for proteolytic 
processing. Seven cathepsin A variants expressed in HEK293T cells were processed 
into large and small subunits (Figure 2.4c), suggesting multiple processing sites can lead 
to mature cathepsin A. Amino-acid sequencing results, alanine-scanning mutagenesis, 
and protease inhibition all point to the specificity of the maturation protease as trypsin-
like. 
2.3.4 Enzymatic activity increases with maturation of cathepsin A to the 51.1 kDa 
form 
Cathepsin A is a serine carboxypeptidase that cleaves terminal amino acids from 
oligopeptides in the lysosome [7, 8]. The carboxypeptidase activity has been studied 
previously with endogenous mature cathepsin A purified from placental tissue using the 
synthetic dipeptide Z-Phe-Leu [62]. To test the activity of the insect cell expressed 
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mature cathepsin A activated by removal of blocking and excision peptides by 
endogenous insect cell proteases, Z-Phe-Leu was used to determine KM and kcat. The 
carboxypeptidase activity was measured by detecting the amount of Leu released using 
the amine reactive reagent TNBS. Cathepsin A activity was highest at pH 4.5 (Figure 
2.5), as is common for lysosomal enzymes. Recombinant human cathepsin A showed a 
KM of 0.04 mM and a kcat of 12.1 s-1, similar to previously reported values for endogenous 
human placental cathepsin A (0.07 mM KM and 35 s-1 kcat) against a comparable 
substrate (Figure 2.5). 
We examined the activity of cathepsin A as a function of its proteolytic 
maturation. The maturation of full-length zymogen into the cleaved mature form was 
followed over time and quantified by SDS-PAGE. At each maturation time point, the full 
kinetic profile of the carboxypeptidase activity of cathepsin A (0.01 mM to 1.0 mM 
substrate concentrations) was measured (Figure 2.5d and e). The increase in 
carboxypeptidase activity of cathepsin A mirrors the amount of proteolytically cleaved 
cathepsin A. Conversion of the intermediate form to the completely processed mature 
protease with large (31 kDa) and small (20 kDa) subunits results in maximal activity. 
2.4 Discussion 
Cathepsin A undergoes processing of the inactive zymogen to generate an active 
mature protease. The structure of the precursor cathepsin A zymogen led to the 
hypothesis that enzymatic activity required cleavage of a 1.6 kDa peptide followed by 
conformational changes in the cap domain [33]. The mass spectrometry, N-terminal 
sequencing, crystallographic, and cellular data presented here are each inconsistent with 
the conformational change model of cathepsin A maturation. Instead, we propose an 
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Figure 2.5: Cleavage of the blocking peptide is important for maximal 
carboxypeptidase activity  
(a) Activity of mature cathepsin A peaks at pH 5.0 (b) Michaelis-Menten plot of 
carboxypeptidase activity against Z-Phe-Leu at different substrate concentrations (0.01 
mM to 1.0 mM). (c) The kinetic parameters for recombinant cathepsin A activity against 
Z-Phe-Leu are compared to those of purified endogenous cathepsin A and its closest 
homolog, yeast carboxypeptidase reported in earlier studies. (d) Analysis of cathepsin A 
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on reducing SDS-PAGE shows the maturation progress of full length cathepsin A into an 
intermediate form upon cleavage, which is further processed to form the mature large 
and small subunits. (e) The maturation of cathepsin A in (c) is quantified and plotted 
against maturation progress by measuring the band intensities of full length (), 
intermediate (), mature large (n) and mature small () subunits. Cathepsin A activity 
as apparent vmax in mM/min (grey bar) measured at each time point plotted against the 
maturation progress shows the increase in activity upon conversion of the intermediate 
to mature form.  
 
 
alternate model, where removal of a larger excision peptide (including the blocking 
peptide), allows direct access of substrate to the active site (Figure 2.6). Maximal 
cathepsin A activity is attained after removal of both the blocking and excision peptides.  
Proteases are generally synthesized as inactive zymogens that undergo 
proteolytic activation to form the active mature enzyme, a mechanism allowing strict 
control of catalytic activity. Proteases use a variety of mechanisms for controlling 
activation. Some (e.g. lipases and caspases) undergo significant conformational 
changes or dimerization to generate a viable active site. In others (e.g. chymotrypsin and 
trypsin), segments of the zymogen are removed either by autocatalysis or limited 
proteolysis, followed by conformational changes to form the functional active site. In 
others (e.g. wheat and metallo-carboxypeptidases, and many other cathepsins), the 
active site is preformed and activation requires only limited proteolysis. Our data 
suggests that cathepsin A is activated in a similar manner to the wheat and metallo- 
carboxypeptidases and other cathepsins.  
The structure of the mature protease shows no appreciable conformational 
changes with respect to the zymogen structure. N-terminal sequencing confirms that 
Ser293 is the first residue of the small subunit, and mass spectrometry analysis 
indicated the cleaved peptide to be 3.3 kDa, suggesting the second cleavage to take 
place after Arg262 or Lys265. These results show that residues 263/266 to 292 are not 
present in the mature protease, and the short segments 259 to 262/265 and 293 to 296 
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are unstructured. A disulfide bond (Cys253-Cys303), conserved across family members, 
connects the polypeptide chain on either side of the cleaved peptide, presumably 
preventing further processing of the mature cathepsin A. In the mature cleaved form of 
cathepsin A, this disulfide bond stabilizes the interface between large and small 
subunits. Additionally mature cathepsin A resists C-terminal degradation by itself or other 
carboxypeptidases by two proline residues, Pro258 in the large subunit and Pro451 in 
the small subunit. The mature cathepsin A is a stable protein that retains full enzymatic 
activity for months after purification.  
Our data indicate specific cleavage sites on the cathepsin A lead to its 
maturation. However, alternate processing sites are also possible. In both biochemical 
and human cellular experiments, substitution of the proposed cleavage sites with 
alanines still allowed processing of cathepsin A. The maturation subdomain (254 to 302) 
has multiple recognition sites for trypsin-like and cathepsin (B, D, K and L) proteases, as 
predicted by PROSPER [63] and SitePrediction [64]. Suppression of multiple potential 
cleavage sites also resulted in processing of cathepsin A when expressed in mammalian 
cells. Cleavage at all these sites can potentially remove the excision and blocking 
peptides and activate cathepsin A. In fact, human cathepsin A has been treated in vitro 
with trypsin and cathepsin L to generate mature cathepsin A with catalytic activity [34, 
58]. In cells, several proteases are capable of limited proteolysis of cathepsin A to 
activate the enzyme, as seen with other cathepsins, which participate in the proteolytic 
processing of endolysosomal proteins in cells [65]. A similar pattern was previously 
reported in the activation of endo-lysosomal proteins such as cathepsin D, which is 
processed by multiple cellular proteases with cleavage at alternate sites [66].  
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Figure 2.6: Model of cathepsin A maturation.  
(a) The originally proposed model for precursor cathepsin A (green) maturation involves 
the cleavage of a 1.6 kDa peptide (285-298, yellow) followed by conformational changes 
in the blocking peptide (272-277, dark blue) and the sequence connecting the blocking 
and excision peptides (278-284, cyan) to allow solvent accessibility of the catalytic triad 
(spheres). (b) We propose an alternative model involving cleavage of a larger 3.3 kDa 
peptide (263-292, that includes the blocking peptide, the 1.6 kDa excision peptide and 
the sequence connecting the two) to form the mature active protease (purple).
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Since tissue distribution of cellular proteases vary widely, susceptibility to multiple 
proteases potentially allows for regulation of cathepsin A activity across many cell types. 
 Our data suggests the complete removal of the blocking peptide in the mature 
cathepsin A generated by endogenous insect cell proteases. The kinetic profile of this 
mature cathepsin A is comparable to that of endogenous mature cathepsin A purified 
from placental tissue. The near equivalence of the human cathepsin A to the well-
characterized enzymatic activity of endogenous cathepsin A suggests that the insect-cell 
expressed human cathepsin A is fully processed into the active form by cellular 
proteases. We further tested the importance of the removal of the blocking peptide on 
activity of cathepsin A by following its activity during the processing steps. A small 
increase in cathepsin A activity was observed as zymogen was cleaved once to form the 
intermediate and mature forms. However, a 40% increase in activity is observed as the 
intermediate form is processed to the fully mature protease. This suggests that the 
second cleavage that results in the removal of the blocking peptide and the excision 
peptide is essential for the complete activation of cathepsin A in vitro and in vivo.  
Cathepsin A is ubiquitously expressed and its importance in prodrug conversion 
and the cardiac system has seen an increase in its potential as a target for 
pharmacological studies. Inhibitors developed against cathepsin A are currently in 
clinical trials. Given the uncertainty in the activation mechanism of cathepsin A and its 
central role in human disease, the results presented here may help to design 
mechanism-based inhibitors, which might be useful as pharmaceuticals. 
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2.5 Methods 
2.5.1 Molecular biology 
 Human protective protein/cathepsin A (CTSA) cDNA (National Center for 
Biotechnology Information Sequence ID: NM_000308.2) was purchased from Harvard 
Institute of Proteomics, DNA Resource Core. The complete cDNA including the native 
human signal sequence was cloned into the pIB/V5-HIS-TOPO-TA vector by gateway 
cloning methods. A His6 tag was engineered after the C terminus of the gene, replacing 
the vector-encoded V5 and His6 epitopes. Plasmid DNA from isolated colonies were 
prepped and sequenced. Mutations in the CTSA gene were generated according to the 
Phusion site-directed mutagenesis kit (Thermo Scientific) by PCR amplification using 
primers coding for the corresponding base changes. For expression in human cells, the 
CTSA gene was cloned into the p3xFLAG-CMV14 vector to encode C-terminally FLAG-
tagged protein. Mutations in the CTSA gene were generated as above. CTSA constructs 
for human-cell expression contained the nucleophile knock out S150A. 
2.5.2 Protein expression and purification  
We expressed and purified Cathepsin A in Tn5 (Trichoplusia ni) insect cells as a 
secreted protein. Adherent cultures were transfected with plasmid DNA in T25 flasks. 
After 2 days, treatment with 100 μg/mL blasticidin for 10 days generated stable cell lines. 
For protein purification, the cells were resuspended into 25 mL of homemade Sfx-
equivalent media and then scaled up to 6 to 10 L in 3 L fernbach flasks (Corning). The 
cells were harvested at 3x106 cells/mL and clarified by centrifugation. The spent media 
was concentrated and buffer exchanged into Ni2+ wash buffer [50 mM phosphate and 
250 mM NaCl] by tangential flow filtration. 
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Cathepsin A was purified by affinity and ion-exchange chromatography using a 
FPLC (BioRad). Cathepsin A was partially purified by the Ni2+ -sepharose FF column (GE 
Healthcare) with elution buffer (50 mM phosphate, 250 mM NaCl, 250 mM imidazole). 
The fractions containing cathepsin A were pooled, concentrated and buffer exchanged 
into 50 mM sodium acetate pH 5.1 and further purified on a SOURCE15 S anion-
exchange column by a gradient of 0-500 mM NaCl. The fractions containing pure 
cathepsin A were buffer exchanged into 20 mM Tris-HCl, 150 mM NaCl and 
concentrated to 1 mg/mL for storage. The purified precursor cathepsin A was observed 
to undergo limited proteolysis over 1-3 weeks, presumably by small amounts of co-
purified endogenous proteases. 
2.5.3 Mammalian cell expression and immunoprecipitation (IP) 
Cathepsin A plasmid DNA in the p3xFLAG-CMV14 vector was transfected into 
HEK293T cells using Lipofectamine (Life Technologies) according to manufacturer’s 
protocol. Cells were harvested 36 h post transfection and lysed in cell lysis buffer. Whole 
cell lysates were immunoprecipitated with anti-FLAG M2 magnetic beads (Sigma-Aldrich) 
for one hour at 4°C. Beads were washed in buffer (50 mM Tris, 150 mM NaCl) and acid 
eluted (100 mM sodium citrate, pH 3). Eluates were analyzed for proteolytic processing 
by western blot using anti-cathepsin A antibody (Rockland Immunochemicals) to detect 
precursor and large subuint cathepsin A. The small subunit of cathepsin A was detected 
by analyzing the whole cell lysate by western blot using anti-FLAG antibody. 
2.5.4 Crystallography  
Cathepsin A was purified and concentrated to 4 mg/mL for sitting drops. Crystals 
grew in 0.1 M sodium formate pH 7.0 (or 0.1M ammonium tartarate), 10% (w/v) 
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polyethylene glycol 3,350 in 7 days. Crystals were flash cooled in liquid nitrogen and X-
ray data were collected at the microfocus beamline NE-CAT 24-ID-C at Argonne 
National Laboratory. X-ray images were processed in HKL2000 [67] and phased by 
molecular replacement using the cathepsin A precursor (PDB ID: 1IVY) in PHASER [68]. 
TRUNCATE [69] reported statistics suggestive of nearly full merohedral twinning in 
crystal Native1, so crystal Native2 (untwinned but lower resolution) was used to 
independently confirm the structure. Model building and validation were done in Coot 
[70] and CCP4i [71] respectively. Refmac5 [72] was used for refinement. For the Native1 
twinned data, amplitude based twin refinement was used during refinement in Refmac5. 
2.5.5 Mass spectrometry  
Insect-cell-expressed cathepsin A glycoprotein was subjected to enzymatic 
deglycosylation with Endoglycosidase H and Peptide-N-Glycosidase F. However, the 
carbohydrate was resistant to enzymatic removal (presumably due to fucosylation [73, 
74]), leading to poor results in electrospray ionization (ESI) experiments. The 
glycosylated protein was subsequently used for Matrix-assisted laser 
desorption/ionization (MALDI) analysis on a Bruker OmniFlex MALDI-TOF MS in linear 
mode to determine masses. Protein samples at different times post purification were 
buffer exchanged into 50 mM ammonium acetate pH 7.4 and mixed with 50 mg/ml 
sinapic acid in 50% acetonitrile and 0.5% trifluoroacetic acid.  
2.5.6 N-terminal sequencing  
Mature cathepsin A was concentrated and run on a reducing SDS-PAGE gel. The 
proteins were transferred to PVDF membrane (Immobilon) and visualized by staining 
with GelCode Blue (Pierce). The band corresponding to the small subunit (~20 kDa) was 
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cut out, washed, dried, and sequenced by 10 cycles of Edman degradation (Harvard 
Microchemistry) with 13 pmol of Ser293 detected. 
2.5.7 Identification of the endogenous protease that cleaves cathepsin A in 
insect cells  
Purified insect cell expressed cathepsin A was concentrated to 0.5 mg/mL in 
storage buffer. Protease inhibitors (benzamidine, Z-VAD-FMK, leupeptin) against 
different protease types was added to three aliquots of the purified cathepsin A, and 
incubated for 72 hours at 4 ºC. Samples were analyzed for cleavage of full-length 
precursor to mature two-chain form by SDS-PAGE, along with purified full-length 
cathepsin A and an aliquot with no inhibitor as controls. 
2.5.8 Activity assays  
Carboxypeptidase activity of cathepsin A was measured using Z-Phe-Leu 
(Sigma) substrate in a two-step assay. Z-Phe-Leu cleavage by PPCA leads to a leucine 
primary amine, which was quantified in a modified trinitrobenzene sulfonate (TNBS) 
assay [75]. Briefly, 40 nM of mature PPCA was added to assay buffer (0.1 M NaOAc and 
0.15 M NaCl, pH 4.5) containing 0.01 mM to 1.0 mM Z-Phe-Leu. Every 15 seconds for 2 
minutes, 10 μL of the reaction was added to 10 μL TNBS (2 mM in 0.2 M sodium borate, 
pH 9.8). After 30 minutes at 27°C, 80 μL of 3 mM NaS2O3 in 0.2 M KH2PO4, pH 4.2 was 
added. Absorbance at 420 nm was compared to controls lacking enzyme and/or 
substrate and calibrated against a standard curve using leucine. The pH profile of 
enzyme activity was determined by varying assay buffers from pH 3.5 to pH 7.0, and the 
resulting plot was fit with: 
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where K1 and K2 are the Ka values for the relevant ionizable groups. Kinetic parameters 
were determined by measuring rate of reaction using 0.01 mM to 1.0 mM Z-Phe-Leu in 
quadruplicate measurements. KM and kcat were extracted from fitting of Michaelis-Menten 
hyperbolae in KaleidaGraph.  
To study the activation of cathepsin A, carboxypeptidase activity was measured 
at multiple time points during maturation. Briefly, cathepsin A purified from insect cells 
was concentrated and incubated at 4°C. Kinetic parameters were measured using 
substrate concentrations 0.01 mM to 1.0 mM of Z-Phe-Leu (as described above) at 
various time points (0-21 days). The processing of cathepsin A at each time point was 
measured by quantifying band intensities on a reducing SDS-PAGE gel using the 
GeneTools software (Syngene). 
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3      CHAPTER 3  
PHARMACOLOGICAL CHAPERONES TARGETING NEU1 
3.1 Introduction 
Lysosomal storage diseases are protein-misfolding diseases caused by 
mutations affecting protein-folding efficiency resulting in loss of function in the lysosome 
[76, 77]. For lysosomal localization, it is essential for proteins to attain a proper folded 
state in the neutral pH of the endoplasmic reticulum (ER) to avoid degradation by the 
ER-associated quality control machinery. Once folded, proteins are trafficked to the 
Golgi where additional modifications such as glycosylation are required for transport to 
the lysosome. In lysosomal storage diseases, many of the disease-causing mutants can 
result in active enzymes in the lysosome, if they are not sequestered in the ER [76, 78].  
The use of small molecules as pharmacological chaperones to assist in the 
folding of mutant proteins as a treatment option is being investigated. Proof-of-concept 
studies for pharmacological chaperone therapy (PCT) have been demonstrated for 
proteins involved in different diseases, including enzymes [79, 80], channel proteins [81-
83], receptors [84-86], and DNA binding proteins [87]. PCT for Tay-Sachs, Fabry, 
Gaucher, GM1 gangliosidosis and other lysosomal storage diseases are currently in 
clinical trials [78]. In the case of enzymes, active-site specific inhibitors at sub-inhibitory 
concentrations have been used to promote folding of the enzymes in the ER [88]. Once 
in the lysosome, the inhibitors dissociate in the presence of high substrate 
concentrations [89].  
Deficiency in lysosomal neuraminidase (NEU1) activity is observed in two 
lysosomal storage diseases, sialidosis [90] and galactosialidosis [91]. Clinical 
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manifestations of both the diseases are similar (described in more detail in chapter 1), 
developing from a loss in neuraminidase function and accumulation of substrates with 
terminal neuraminic acids. Currently there are no approved treatments or ongoing 
clinical trials for sialidosis and galactosialidosis.  
In principle, PCT may be applied to twenty-two of the forty sialidosis causing 
missense mutations in NEU1, including single amino acid substitutions that affect protein 
folding or those that are present on the surface. These substitutions are unlikely to affect 
the catalytic properties of NEU1, and may be active. NEU1 activity is an important factor 
in the pathogenesis of galactosialidosis, as suggested by similarities in types of 
substrates accumulated and clinical manifestations in sialidosis and galactosialidosis. 
Thus, stabilizing wildtype NEU1 in cathepsin A deficient cells is an alternate treatment 
approach in galactosialidosis. In this study we expressed and purified human NEU1 in 
insect cells and determined its kinetic parameters for the first time, independent of its 
binding partners (cathepsin A and β-gal). We report biochemical and cellular data 
supporting the application of two neuraminidase inhibitors α-D-N-acetylneuraminic acid 
(NANA), the product of neuraminidase reaction, and N-Acetyl-2,3-dehydro-2-
deoxyneuraminic acid (DANA), a pan-neuraminidase inhibitor as pharmacological 
chaperones for NEU1. The small molecules presented in this study provide a good 
scaffold for the development of further pharmacological chaperones. 
3.2 Experimental strategy 
In this work we sought to determine the enzymatic profile of NEU1 in vitro outside 
of the lysosomal multi-enzyme complex. The pH optima and kinetic parameters of 
human lysosomal neuraminidase (NEU1) expressed in insect cells were determined 
using the synthetic substrate 2-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-
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MU-NANA). Neuraminidase inhibitors (NANA and DANA) were analyzed for their use as 
scaffolds for chaperones in PCT using the active NEU1. NANA is the product of the 
neuraminidase reaction that can undergo ring opening and closing at the C2 position 
(Figure 3.2 a). However, in DANA a double bond is present between the C2 and C3 
positions, disallowing the opening of the ring (Figure 3.2 b). Due to this, DANA may be a 
better inhibitor of neuraminidases. The binding affinity of the inhibitors to NEU1 was 
determined by inhibition assays. Tryptophan fluorescence and pulse proteolysis 
techniques were used to monitor their effect on the stability and protease susceptibility of 
NEU1. The effect of these molecules on expression of NEU1 in HEK293T cells was also 
studied to test the chaperoning effect in cells.  
3.3 Results 
3.3.1 NEU1 exhibits exo-neuraminidase activity outside of the lysosomal 
complex 
To understand the effect of the inhibitors on NEU1 activity, it was important to 
first characterize the neuraminidase activity of human NEU1 in vitro in the absence of its 
binding partners (cathepsin A and β-galactosidase). NEU1 is an exo-neuraminidase that 
cleaves terminal neuraminic acids on glycoproteins and other glycoconjugates. To test if 
NEU1 is active in vitro, the rate of cleavage of the synthetic substrate 2-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4MU-NANA) was measured using 
insect cell expressed human NEU1. Fluorescence at 450 nm was used to determine the 
concentration of cleaved neuraminic acid. Neuraminidase activity was highest between 
pH 4 and 4.5, similar to other lysosomal enzymes. At pH 4.5 NEU1 showed a KM of 
1.23 mM and kcat of 2.14 min-1 (Figure 3.1a, b). These values are comparable to  
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Figure 3.1: NEU1 is active in vitro in the absence of cathepsin A 
(a) pH profile of neuraminidase activity of NEU1 shows optimal activity between pH 4 
and 4.5. (b) Michaelis Menten plot of neuraminidase activity of NEU1 at pH 4.5 against 
4-MU-NANA at different substrate concentrations (0.1 mM to 10 mM). (c) The kinetic 
parameters for NEU1 activity against 4-MU-NANA are compared to those of purified 
NEU3 (membrane bound human neuraminidase) reported in earlier studies [92]. 
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Figure 3.2: NANA and DANA bind to and inhibit NEU1 
Structures of NANA and DANA are shown in (a) and (b), respectively. Dose response 
plots of NANA (a) and DANA (b) inhibition of NEU1 activity. NEU1 activity against 1 mM 
4-MU-NANA substrate is shown as % residual activity at different inhibitor 
concentrations (NANA: 0.05 mM to 10 mM, DANA: 0.05 mM to 5 mM). (c) The inhibition 
parameters for NANA and DANA on NEU1 activity. 
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published values for human membrane associated neuraminidase (NEU3) [92] against 
the same substrate (Figure 3.1c) [92]. 
3.3.2 NANA and DANA are competitive inhibitors of NEU1 
An effective pharmacological chaperone binds reversibly to the active site of the 
target protein to facilitate proper folding. The pharmacological chaperone must 
consequently dissociate to allow substrate binding and catalysis. Inhibition profiles were 
determined by competition assays with fluorogenic substrates. NANA and DANA showed 
an IC50 of 1.23±0.05 mM and 1.30±0.05 mM respectively using 4-MU-NANA as substrate 
(Figure 3.2 c). Ki for the inhibitors was calculated to be 0.67±0.01 mM and 0.71±0.01 
mM from the IC50 (Figure 3.2 d). 
3.3.3 Inhibitors influence the folding of NEU1 in vitro 
To determine the effect of NANA and DANA on the stability of NEU1, intrinsic 
tryptophan fluorescence spectrum was measured in increasing concentrations of urea. 
Tryptophan residues have different emission max (λmax) depending on the polarity of the 
environment when excited at 295 nm. The λmax for a buried tryptophan residue ranges 
from 315 to 330 nm, which increases upto 351 nm when solvent exposed. Since 
tryptophan residues are generally buried in the protein, monitoring the tryptophan 
fluorescence spectrum on excitation at 295 nm can provide insight in to the folding state 
of the protein in different concentrations of denaturant. NEU1 has eight tryptophan 
residues that are predicted to be spread throughout the protein structure (when mapped 
on a model). The emission spectra of all the samples (0-8 M urea) were normalized to 
maximum intensity for each sample, and the change in the λmax was monitored as an 
indication of the foldedness of NEU1.  
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Figure 3.3: NANA and DANA stabilize NEU1 
 
(a) Intrinsic tryptophan fluorescence spectra of empty (top panel), NANA bound (middle 
panel) and DANA bound (bottom panel) NEU1 in increasing urea concentrations. 
Weighted fits of spectra normalized to individual λmax are shown in the inset panels with 
the λmax at each urea concentration indicated by colored arrows. The λmax for NEU1 with 
NANA and DANA is ≤ 336 nm up to 5 M urea (green dashed line) compared to > 336 nm 
for empty NEU1 in all urea concentrations. NEU1 completely unfolds in more than 6 M 
urea with a λmax of 351 nm (red dashed line). (b) Unfolding of NEU1 as fraction 
denatured as a function of urea concentration. The λmax for all NEU1 ( ), DANA 
bound ( ) and NANA bound ( ) spectra normalized to NANA bound NEU1 in 0 
M urea (folded) as a function of urea concentration shows a higher baseline for empty 
NEU1.  
 
In all higher urea concentrations the λmax of NEU1 without inhibitor shifts to 337 
nm or greater, which is observed only in 5 M or higher urea concentrations for inhibitor 
bound NEU1 (Figure 3.3 a). Calculation of fraction denatured NEU1 shows that the 
baseline (folded) for NEU1 is higher than that with NANA and DANA. NEU1 is denatured 
by 50% in 5 M urea as opposed to only 20% when bound to NANA and DANA (Figure 
3.3 b). 
3.3.4 NANA and DANA confer resistance to proteolysis by thermolysin 
Optimally folded proteins are less susceptible to proteolysis by proteases since 
the number of accessible protease recognition sites is minimized. An increase in 
degradation is seen as the protein unfolds (thermal or chemical denaturation) leading to 
changes in band intensity when analyzed by SDS-PAGE. This technique is used to 
monitor changes in stability of NEU1 in the presence of ligand. Thermolysin completely 
degraded NEU1 in 1 M urea, which was blocked by incubation with 10 mM inhibitor 
(Figure 3.4 a, b). Susceptibility to proteolysis by thermolysin was determined in the 
presence of increasing concentrations of inhibitors and analyzed by quantifying band 
intensities on SDS-PAGE gel.  
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Figure 3.4: NANA and DANA prevent unfolding of NEU1 in low urea 
concentrations  
(a) Pulse proteolysis of NEU1 with thermolysin in increasing concentrations of urea (0 – 
1.5 M). Coomassie stained gel shows complete degradation of NEU1 in 1 M urea.        
(b) Pulse proteolysis of NEU1 bound to inhibitors in urea (0 – 6 M). Coomassie stained 
gels show incubation with 10 mM NANA (top panel) or DANA (bottom panel) protects 
NEU1 from proteolysis in urea concentrations greater than 1 M.  
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Figure 3.5: NANA and DANA confer resistance to proteolysis in urea  
NANA (a) and DANA (b) reduce NEU1 degradation by thermolysin in 2 M urea. 
Coomassie stained gels show increased protection by inhibitor at 25 mM and above. The 
band intensities for NEU1 normalized against NEU1 in the sample without inhibitor or 
thermolysin (lane 2 in both gels) respectively show effect of inhibitors on NEU1 (graph, 
top panel). Band intensities of thermolysin added to the reactions are plotted for each 
inhibitor (bottom panel). 
 
Reactions were carried out in 2 M urea, as NEU1 is not susceptible to thermolysin in pH 
7 buffers. NANA and DANA confer resistance to degradation at concentrations greater 
than 25 mM (Figure 3.5 a, b). 
3.3.5 Inhibitors affect NEU1 expression in cells 
To test if the inhibitors stabilize NEU1 in cells, mammalian cells (HEK293T) 
expressing NEU1 were incubated with different concentrations of the NANA and DANA.  
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Figure 3.6: NANA and DANA function as chaperones in HEK293T cells 
Anti-NEU1 western blot of whole cell lysates (top panel) shows the effect of inhibitors on 
NEU1 overexpressed in HEK cells. Quantified band intensities were normalized against 
NEU1 (grey bar) without inhibitors for comparison. Proteasome inhibitor MG132 (dark 
grey bar), DANA (brown bars) and NANA (pink bars) increased NEU1 expression in a 
dose dependent manner.
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Cells expressing NEU1 (no inhibitor) were incubated with the proteasome inhibitor, 
MG132 to determine if NEU1 is degraded rapidly in the ER. Ligands for chaperone 
therapy bind to target proteins in the ER and increase their levels in the lysosome by 
facilitating proper folding. Expression of NEU1 increases significantly in the presence of 
the proteasome inhibitor MG132, indicating targeting of NEU1 to the ER-associated 
degradation machinery. A dose-dependent increase in NEU1 expression is observed 
with NANA and DANA (Figure 3.6).  
3.4 Discussion 
NEU1 is an ubiquitously expressed human neuraminidase, deficiency of which 
leads to accumulation of neuraminic acid containing glycoproteins and glycolipids in two 
lysosomal storage diseases, sialidosis and galactosialidosis. Both diseases have severe 
central nervous system (CNS) involvement, emphasizing the need for treatment options 
in addition to the current ERT and gene therapy studies. In this study we introduce for 
the first time the concept of pharmacological chaperone therapy targeting NEU1 as an 
alternate avenue for treatment of sialidosis and galactosialidosis. NANA and DANA bind 
to NEU1 and influence its folding and stability in vitro, and we further show stabilization 
of NEU1 in human cells after uptake of the inhibitors.  
Approved therapies for a limited number of lysosomal storage diseases include 
enzyme replacement therapy (ERT), substrate reduction therapy and pharmacological 
chaperone therapy (PCT) [93, 94]. Enzyme replacement therapy involves periodic 
infusions of recombinant expressed protein to compensate for the deficient enzyme. This 
method has been successfully implemented in the treatment of Fabry, Gaucher, Pompe 
diseases and Mucopolysaccharidosis (MPS) I, II and VI [93]. However, ERT is 
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complicated by very high costs, development of immune response towards administered 
protein and limitations with respect to tissue distribution such as in the central nervous 
system. Substrate reduction therapy aims at reducing the concentration of the toxic 
substrates that accumulate in cells as a result of enzyme deficiency.  
Pharmacological chaperone therapy is based on the potential of ligands such as 
active site-binding competitive inhibitors to aid in the folding of mutant enzymes, thereby 
stabilize and prevent degradation of target protein by ERAD machinery [95]. PCT is a 
very good alternative or addition to ERT for treatment of diseases with nervous system 
involvement. 
ERT, gene therapy and small molecules targeting cellular proteostasis are 
currently being explored for the treatment of sialidosis. ERT with baculovirus expressed 
NEU1 alone or in combination with cathepsin A in a NEU1-/- mouse showed uptake of 
the proteins and significant reduction in accumulated substrates in most non-neuronal 
tissue types [31]. However, severe immunogenic responses were observed in the 
treated mice. Expression of cathepsin A by gene therapy using an AAV2/8 vector in a 
mouse model of type I sialidosis also resulted in clearance of substrates and may one 
day be a viable option for sialidosis patients carrying some type I mutations [46]. 
Modulation of cellular proteostasis by small molecules to increase folding of mutant 
proteins was proposed as a treatment option for protein misfolding diseases such as 
lysosomal storage diseases [76]. In one such study, a combination of MG132 (a 
proteasome inhibitor) and celastrol (a modulator of heat shock protein (HSP) chaperone 
levels) increased the expression and lysosomal localization of NEU1 in cells [96]. 
However, a small molecule or pharmacological chaperone specifically targeting NEU1 
had not been reported prior to this work.  
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The majority of disease-causing mutations in sialidosis and galactosialidosis (and 
lysosomal storage diseases in general) destabilize the proteins in the ER resulting in 
degradation by the ERAD machinery. Similar to other lysosomal storage diseases a 
minimum threshold of 10 - 15 % residual activity in the lysosome is hypothesized to be 
sufficient to alleviate disease pathology in sialidosis and galactosialidosis [31]. This is 
often achieved in PCT (Figure 3.7), and has been successfully demonstrated for 
treatment of Fabry, Pompe and Gaucher diseases [89, 97-99]. In this report we studied 
the viability of α-D-N-acetylneuraminic acid (NANA, the product of the neuraminidase 
reaction) and N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid (DANA, a pan-
neuraminidase inhibitor) as PCT molecules targeting NEU1.  
To better understand inhibition of NEU1, its neuraminidase activity was 
characterized by measuring kinetic parameters using the synthetic substrate 4-MU-
NANA. We show that NEU1 has neuraminidase activity and the kinetic parameters are 
comparable to previously reported values for NEU3 activity [92] against the same 
substrate. In contrast to literature reports of specific activity (1.5 μM hr-1mg-1) [57], the 
NEU1 in our assay is 1000-fold more active, demonstrating the catalytic capability of 
NEU1 independent of the cathepsin A complex. NANA and DANA inhibited NEU1 
neuraminidase activity with a Ki of 0.67±0.01 mM and 0.71± 0.01 mM respectively 
showing that they bind reversibly to NEU1.  
Our tryptophan fluorescence and pulse proteolysis data show that binding of 
NANA and DANA in increasing concentrations of urea influence NEU1 folding and confer 
resistance to proteolysis. NEU1 without inhibitor is completely degraded in 1 M urea as 
compared to when bound to inhibitor. Additionally, in 2 M urea, increasing concentrations 
of inhibitor results in progressively more resistance to proteolysis by thermolysin.  
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Figure 3.7: Pharmacological Chaperone Therapy (PCT) for lysosomal storage 
diseases 
The fate of a lysosomal protein from point of synthesis to trafficking to the lysosome is 
described in a step-wise manner. The pathway for wildtype protein (2a) is compared to 
those hypothesized to occur in case of mutant protein (2b) and mutant protein in the 
presence of a pharmacological chaperone (2c).
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In cells NEU1 is proposed to depend on cathepsin A for activity and stability 
[100]. The significant increase in the level of overexpression of NEU1 in human 
cells (HEK293T) upon inhibition of the proteasome (using 10 µM MG132) suggests that 
NEU1 may be degraded in cells in the absence of cathepsin A. Likewise, we show that 
addition of NEU1 inhibitors also increases expression levels in a dose-dependent 
manner suggesting inhibitor mediated optimal folding of NEU1 in the ER. 
Our biochemical and cellular data support the use of NEU1 inhibitors as 
pharmacological chaperones for reduction of accumulated substrates in sialidosis and 
galactosialidosis. Analysis of inhibitors with higher specificity towards NEU1, such as 
those generated by changing the functional group at the C9 position of neuraminic acid 
[101] may improve the PCT model proposed in this study. Additionally, oseltamivir 
phosphate and zanamivir (influenza neuraminidase inhibitors) that are approved for 
treatment of flu, have been proposed as a treatment for prostrate cancer (targeting 
NEU1 function on plasma membrane). These neuraminidase inhibitors might be 
repurposed to function as pharmacological chaperones [45]. Potential application of 
DANA (the scaffold for many neuraminidase inhibitors, including those mentioned above) 
as a pharmacological chaperone for NEU1 presented in this work suggests new avenues 
for treatment of sialidosis and galactosialidosis.  
3.5 Methods 
3.5.1 Plasmid generation 
Insect cell expression: NEU1 cDNA was purchased from Open Biosystems 
(Clone ID: 4101695). The gene including the native signal sequence was PCR amplified 
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as per the Phusion High Fidelity polymerase kit (NEB). Primers corresponding to the 
beginning and end of the NEU1 gene including a C-terminal His6 tag were used to 
amplify the gene for cloning into the gateway pENTR/D-TOPO entry vector (Life 
Technologies). Sequence verified entry clone (construct 1, Table 3.1) was then used to 
clone the gene into pIB/V5-HIS-DEST vector for expression in insect cells, using the LR 
clonase kit as per manufacturer’s protocol (construct 2, Table 3.1). Phusion site-directed 
mutagenesis kit was used to insert a His6, TEV cleavage site and Gly4 spacer at the N-
terminus and insert a stop codon after the last residue of NEU1 (construct 3, Table 3.1).  
Mammalian cell expression: Construct 1 was cloned into pcDNA3.2 vector by 
LR colonase reaction to generate untagged version of NEU1 (construct 4, Table 3.1). 
Site directed mutagenesis was done to remove the stop codon in construct to include the 
V5 epitope and His6 tag of the pcDNA3.2 vector (construct 5, Table 3.1). Primers with 
Not1 and Xba1 restriction sites were used for PCR amplification of the gene from 
construct 3 to clone it into the p3xFLAG-CMV14 vector for expression of N-terminal 
tagged NEU1 in mammalian cells. 
3.5.2 NEU1 expression and purification 
Insect cell expression: N-terminal tagged NEU1 (construct 3, Table 3.1) was 
transfected into Tn5 insect cells (Invitrogen) using cellfectin as per manufacturer’s 
protocol and stable cell lines were established by selection with blasticidin. NEU1 is 
secreted into the culture medium due to the native signal sequence. The cell lines were 
scaled up to 4L cultures and harvested at a density of 3.5 million cells/mL by spinning 
down the cells and collecting the supernatant. Culture supernatant was concentrated 
and buffer exchanged into Ni-wash buffer (50 mM phosphate pH 7, 250 mM NaCl) by 
tangential flow filtration. NEU1 was purified by Ni-affinity chromatography using the Ni-
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elution buffer (50 mM phosphate pH 7, 250 mM NaCl, 250 mM imidazole). Fractions 
containing NEU1 were collected and purified further by cation exchange chromatography 
(SourceQ). To generate untagged version of NEU1 fractions containing NEU1 were 
pooled, concentrated and incubated with TEV protease (TEV-His6) overnight. Cleaved 
NEU1 was then purified from the TEV protease by Ni-affinity chromatography. The flow 
through was collected and buffer exchanged into the storage buffer (20 mM Bis-tris pH 
6.0, 150 mM NaCl) and stored at 1 mg/mL. 
Mammalian cell expression: NEU1 constructs were transfected into HEK293T 
cells using lipofectamine (Life Technologies) as per manufacturer’s protocol. Cells were 
harvested after 36 hours and expression tested by western blot using anti-NEU1 
antibody (Rockland Immunochemicals).  
3.5.3 Enzyme kinetics 
Exosialidase activity of NEU1 was measured using the synthetic substrate 2-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-MU-NANA, Gold Biotechnology) by 
monitoring the fluorescence of the released 4-MU (excitation at 365 nm and emission at 
450 nm). pH profile of neuraminidase activity was measured by adding 45 µM of NEU1 
to assay buffer of different pH (pH 3.0 to 7.0) and 5 mM 4-MU-NANA. Measurements 
were taken on a Spectra Max5 plate reader every 2 minutes for 30 minutes. Amount of 
cleaved 4-MU was measured by comparing the fluorescence emission at 450 nm to a 4-
MU standard curve. The resulting plot was fit with: 
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where K1 and K2 are the Ka values for the relevant ionizable groups. Kinetic parameters 
at pH 4.5 (in 100 mM NaOAc) were determined by measuring rate of reaction using 0.1 
mM to 10 mM 4-MU-NANA. KM and kcat were determined from Michaelis-Menten 
hyperbolae derived from initial reaction rates at different concentrations of substrate in 
KaleidaGraph. Error bars were generated for all activity assays from triplicates.  
3.5.4 Inhibition assay 
The inhibitory effect of α-D-N-acetylneuraminic acid (NANA) and N-Acetyl-2,3-
dehydro-2-deoxyneuraminic Acid (DANA) on NEU1 was determined. The rate of 4-MU-
NANA (1 mM) cleaved by NEU1 was measured in the presence of increasing 
concentrations of inhibitor (0.05 mM to 10 mM NANA or 0.05 mM to 5 mM DANA) at pH 
4.5. The IC50 was extracted from the activity versus log of inhibitor concentration plot fit 
by the following equation in KaleidaGraph:  
Equation: 
€ 
y = ymax + (ymax − ymin )
1+ ( xxmid
)^b
  
where ymax is the activity value without inhibitor, ymin is value of fully inhibited, xmid is the 
mid point of transition and b is the slope of the transition. The Ki was determined from 
this by the following equation for each inhibitor:  
Equation: 
€ 
Ki =
IC50
1+ S[ ]KM
  
where, S is the substrate concentration used in the inhibition assay and KM is the 
Michaelis-Menten constant for NEU1 with the substrate used. 
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3.5.5 Unfolding by intrinsic tryptophan fluorescence  
Intrinsic tryptophan fluorescence of NEU1 (eight tryptophan residues per 
monomer) was measured in the presence of urea to monitor unfolding. 1 µM of NEU1 
was incubated with increasing concentrations of urea (0 – 8 M) for 18 hours at room 
temperature. To test the effect of inhibitors, NEU1 was incubated with 25 mM inhibitor for 
2 hours prior to addition of urea. Fluorescence was measured on a PTI instrument by 
excitation at 295 nm and emission scan from 302 nm to 380 nm.  
3.5.6 Protease susceptibility by pulse proteolysis 
The stability of NEU1 as determined by susceptibility to proteolysis was 
measured by pulse proteolysis with thermolysin. 1 µM NEU1 was incubated with 
increasing concentrations of urea for 18 hours at room temperature in buffer (100 mM 
phosphate pH 7, 150 mM NaCl). 1 µL of 1 mg/mL thermolysin (Sigma) was added to the 
samples, and the reaction was stopped by 20 mM EDTA. Proteolysis of NEU1 was 
detected by running a SDS-PAGE gel and monitoring band intensity. To test the effect of 
inhibitors NEU1 was incubated with 10 mM of inhibitor for two hours prior to addition of 
urea. To determine the concentration of inhibitor required to protect NEU1 from 
degradation, increasing concentrations of inhibitors were incubated with NEU1 in 2 M 
urea and degree of proteolysis was monitored as mentioned above.  
3.5.7 HEK cell expression and cellular stability  
The effect of the inhibitors on NEU1 in human cells was determined in HEK293T 
cells by monitoring its expression in the presence and absence of the inhibitors. NEU1 in 
the pcDNA3.2 expression vector (construct 4) was transfected into HEK293T cells using 
lipofectamine as per manufacturer’s protocols. 24 hours after transfection inhibitors at a 
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concentration of 50 mM was added to the media and incubated for a further 24 hours. 
Cells were harvested, lysed and analyzed by anti-NEU1 western blots for NEU1 
expression levels. Proteasome inhibitor MG132 was also added to see if NEU1 was 
being targeted to the ERAD pathway. GAPDH levels were also analyzed as loading 
controls.  
  62	  
 
 
 
Table 3.1: NEU1 constructs 
 
Construct 
No. 
Vector Expression 
system 
Protein 
1. pENTR/D-TOPO Non-expression 
vector 
None 
2. pIB/V5-HIS-DEST Insect NEU1-His6 
3. pIB/V5-HIS-DEST Insect  His6-TEV-GG-NEU1 
4. pcDNA3.2 Mammalian NEU1 
5. pcDNA3.2 Mammalian NEU1-V5-His6 
6. p3xFLAG-CMV14 Mammalian His6-TEV-GG-NEU1 
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4      CHAPTER 4 
CHARACTERIZATION OF THE NEU1-CATA COMPLEX 
4.1 Introduction 
Lysosomal enzymes have evolved to be properly folded and functional in the low 
pH environment of lysosomes. However, as mentioned in chapter 3, the endo-lysosomal 
enzymes also need to fold correctly in the neutral pH of the endoplasmic reticulum (ER) 
first, to enable further essential post-translational processing and modifications required 
for transport to the lysosome. This is achieved in multiple ways, the foremost being 
chaperone-mediated. Some ER proteins (termed chaperones) such as 
calnexin/calreticulin interact with nascent polypeptide chains to aid in their folding. Some 
proteins, including carboxypeptidase Y (a yeast vacuolar protease homologous to 
cathepsin A) [102] and cathepsin D [66], are synthesized with N- or C-terminal 
extensions (pro-sequences that might act as intramolecular chaperones) required for the 
folding of the protein. These sequences or domains are typically cleaved off upon endo-
lysosomal localization in some cases [103]. Formation of protein complexes in the ER 
could prevent misfolding, aggregation or non-specific proteolysis of a folded protein 
during the next steps in the secretory pathway. This type of complex has been 
hypothesized for the lysosomal multi-enzyme complex (of cathepsin A (CATA), 
neuraminidase 1 (NEU1), β-galactosidase (GLB1) and galactosamine-6-sulfatase 
(GALNS)). 
In cathepsin A deficiencies (known clinically as galactosialidosis), a complete 
reduction in endogenous NEU1 protein levels [17] and partial reduction in β-
galactosidase [54, 104] activities are observed, demonstrating their interdependence [15, 
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21]. This effect on NEU1 and GLB1 activity can be restored by supplementing with wild-
type cathepsin A (either by transfection of CTSA gene or uptake of purified protein) [30, 
31]. The reduction in NEU1 and GLB1 activities are attributed to their rapid degradation 
in the cells, and led to the hypothesis that complex formation is important for the stability 
of NEU1 and GLB1 [21, 54, 104-106]. Additionally, in mammalian cells, the diffused ER 
localization of expressed NEU1 is converted to distinct puncti (characteristic of 
lysosomal localization) by co-transfection of cathepsin A [16]. Addition of the proteasome 
inhibitor MG132 and celastrol (a small molecule that influences activity of cellular 
chaperones) to cells reduced the targeted degradation of NEU1, thereby increasing its 
lysosomal concentrations [96]. Moreover, deficiency in neuraminidase activity in purified 
NEU1 and in cathepsin A-deficient cells led to the hypothesis that cathepsin A activates 
NEU1 by inducing conformational changes [17, 53, 57]. 
Early studies performed on the lysosomal complex purified from tissue samples 
demonstrate a high molecular weight multi-enzyme complex (~1.3 MDa) with multiple 
copies of each component [17, 105]. Although a heterodimer (one monomer of each) 
was proposed for the NEU1-CATA binary complex [57], very little is understood about 
the stoichiometry of the complex or the binding interfaces on each of the components of 
the complex. In this study we confirm the binary NEU1-CATA complex by pull down and 
binding experiments and provide further insight into the binding interface on NEU1. We 
further demonstrate that complex formation does not affect NEU1 activity, but may affect 
its stability. These experiments clarify earlier reports of the binary complex and will be 
valuable for studies of other proteins in the lysosomal complex.  
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4.2 Experimental strategy 
The NEU1-CATA complex is a component of the lysosomal multi-enzyme 
complex. In the current work we sought to investigate the binding interface on NEU1 for 
cathepsin A by immunoprecipitation (IP) and biochemical pull down methods. The effect 
of complex formation on the activity and thermal stability of NEU1 was analyzed by 
monitoring activity and changes in molar ellipticity as a function of temperature using 
circular dichroism (CD), in the presence and absence of cathepsin A. 
4.3 Results 
4.3.1 NEU1 and cathepsin A interact to form a binary complex 
To validate the binary complex outside of the multi-enzyme complex, the NEU1-
CATA interaction was studied by Surface Plasmon Resonance (SPR). SPR monitors 
changes in refractive index when ligand is passed over immobilized analyte. It is a 
sensitive technique with the results recorded as sensorgrams (response units (RU)-time 
plots). NEU1 (ligand) binding to cathepsin A (analyte) was analyzed by flowing different 
concentrations of NEU1 in buffer over cathepsin A (immobilized on a CM5 chip by amine 
coupling) until equilibrium binding was reached. Sensorgrams showed increase in the 
RU upon injection of NEU1, reaching equilibrium in 60 seconds post injection. Control 
experiments with a non-lysosomal protein Nickel superoxide dismutase (NiSOD) showed 
no binding, when used as a ligand (by flowing over immobilized cathepsin A) and as 
analyte (by flowing NEU1 over immobilized NiSOD). A concentration-dependent 
increase in the RU was observed when different dilutions of NEU1 were passed over 
cathepsin A, validating the formation of the binary complex in vitro (Figure 4.1). 
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Figure 4.1: NEU1 forms a binary complex with cathepsin A 
SPR senorgrams of NEU1 interaction with cathepsin A (dark grey) seen as binding 
events with increasing concentration of NEU1 passed over immobilized cathepsin A on a 
CM5 chip. The sensorgram of a non-lysosomal protein (NiSOD) passed over 
cathepsin A (light grey) shows no binding event.   
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Figure 4.2: Isolation of NEU1-cathepsin A complex 
(a) Anti-NEU1 (lanes 1-4) and anti-cathepsin A (lanes 5 and 6) western blots of samples  
immunoprecipitated using anti-FLAG antibody against the FLAG epitope on cathepsin A. 
Only NEU1 with a C-terminal tag (lane 2) cannot interact with cathepsin A and cannot be 
pulled down. (b) in vitro pull down with insect-cell expressed NEU1 (untagged) and 
cathepsin A (C-terminal His6 tag) on Ni-NTA resin (top panel) eluted with imidazole 
shows NEU1 in the elution. In vitro pull down of insect-cell expressed tagged NEU1 (C-
terminal His6 tag) with cathepsin A (N-terminal Strep tag, C-terminal His6) on strep-tactin 
resin showing no NEU1 in the elution due to lack of complex formation.  
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4.3.2 C terminus of NEU1 is involved in complex formation 
To gain insight into the binding interface on NEU1, complex formation was 
analyzed by co-transfection of a variety of tagged versions of NEU1 with CATA-3xFLAG 
in HEK293T cells. Cathepsin A immunoprecipitated (IP) from whole cell lysates (using 
anti-FLAG antibody) was detected by anti-CATA western blot. The ability of NEU1 to 
interact with cathepsin A was determined by analyzing the IP elution for NEU1 co-eluted 
with cathepsin A by anti-NEU1 western blot. Only the untagged or N-terminal tagged 
NEU1 (Figure 4.2 a) co-eluted with cathepsin A in the IP, suggesting C-terminal tag 
mediated interference in complex formation. This was also observed with insect cell 
expressed recombinant proteins (Figure 4.2 b). Untagged NEU1 interacted and co-
eluted with CATA-His6 from Ni-NTA beads on addition of imidazole (top panel). However, 
NEU1-His6 did not interact with Strep-CATA-His6 and was eluted from the strep-tactin 
resin in the wash buffer (bottom panel), and cathepsin A eluted in the elution buffer 
(containing 2.5 mM desthiobiotin). To rule out interference of N-terminal Strep tag on 
CATA on binding to NEU1, IP with an N-terminal tag on CATA was studied in HEK293T 
cells. Addition of the tag on cathepsin A did not affect the interaction with NEU1 in 
HEK293T suggesting no interference (Figure 4.2). However, it is possible that the proper 
controls with the strep-tagged versions must ne performed to confirm this. The 
biochemical and cellular pull down experiments suggest that an unmodified C terminus 
of NEU1 is important for interaction with cathepsin A. 
4.3.3 Cathepsin A does not influence NEU1 activity 
NEU1 exists in a multi-enzyme complex in cells, unlike other human 
neuraminidases. Cathepsin A has been proposed to bind NEU1 and activate it by 
inducing conformational changes. To test kinetic properties of NEU1, we expressed and  
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Figure 4.3: Tagged and untagged forms of NEU1 have comparable neuraminidase 
activity 
(a) Michaelis-Menten profile of neuraminidase kinetic assay performed with untagged 
NEU1 is comparable to that by C-terminally tagged NEU1 (b). (c) The values for the kcat 
and kcat/KM are compared in the table. 
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Figure 4.4: NEU1 neuraminidase activity shows little change in activity in the 
presence of cathepsin A 
(a) Fluorescence intensity of 4-MU cleavage by NEU1 alone (orange) and molar ratios of 
NEU1 and cathepsin A (1:1 light grey, 1:4 dark grey and 1:8 black) of NEU1 and 
cathepsin A. Data points from 10 mins onwards were used to calculate initial velocities 
(b) and normalized to NEU1 activity (orange bar). (c) NEU1 activity measured in this 
study is 1000-fold greater than published reports [57]. 
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purified GG-NEU1 (Gly-Gly-NEU1, generated after cleavage of N-terminal affinity tag 
from purified His6-TEV-G-NEU1 by TEV protease) and NEU1-His6 in insect cells. In the 
absence of cathepsin A, both versions of NEU1 were capable of binding and turning over 
substrate (4-MU-NANA) at pH 4.5, at a rate comparable to NEU3, the membrane bound 
human neuraminidase (Figure 4.3). To test if cathepsin A affected NEU1 activity, NEU1 
was incubated with increasing molar concentrations of precursor cathepsin A, and 
neuraminidase activity was measured (Figure 4.4). The rate of neuraminic acid cleavage 
was 12.16±0.22 (for a NEU1: CATA ratio of 1:1), 11.21±0.34 (1:4 ratio) and 9.85±0.38 
(1:8 ratio) μM 4-MU/min, compared to 9.88±0.61 μM 4-MU/min for NEU1 alone. 
Incubation with cathepsin A resulted only in a 20% increase in the presence of cathepsin 
A, unlike the two-fold increase in NEU1 activity reported [57] in previous studies (Figure 
4.4 b). The NEU1 activity without cathepsin A reported here (specific activity 
12.8x103 µMol hr-1 mg-1) is a 1000-fold higher than reported activity of NEU1 
(1.8 µMol hr-1 mg-1). The reported increase in activity upon addition of cathepsin A 
(3.8 µMol hr-1 mg-1) at pH 6.5 and 5.0 is insignificant compared to the activity reported in 
our assay (Figure 4.4 c). 
4.3.4 Complex formation increases NEU1 stability 
Although cathepsin A does not markedly affect the catalytic capability of NEU1, it 
remains possible that NEU1 depends on cathepsin A for stability and resistance to 
proteolysis in cells. We investigated the stability of NEU1 with and without cathepsin A to 
further understand the observation that NEU1 is rapidly degraded in cells in the absence 
of cathepsin A. The thermal stability of NEU1 was determined by monitoring molar 
ellipticity from 200 to 250 nm by circular dichroism at different temperatures, to follow 
spectral changes in the folded and unfolded protein at pH 4.5 and pH 7.0. The thermal  
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Figure 4.5: Complex formation increases stability of NEU1 and cathepsin A 
(a) Circular dichroism (CD) spectra of NEU1 and cathepsin A individually and in complex 
at pH 4.5 (left column) and pH 7.0 (right column). Spectrum at 20ºC shows CD signal of 
native or folded protein () and spectrum at 85ºC shows CD signal of unfolded or 
denatured protein (). (b) Thermal melting points of protein samples at pH 4.5 (left 
panel) monitored at 222 nm and at pH 7.0 (right panel) monitored at 235 nm. Molar 
ellipticity measured at each temperature was normalized to that at 85ºC (100% 
denatured) for each corresponding protein sample.  
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melting temperature (Tm) was calculated from the plot of molar ellipticity versus 
temperature (at 222 nm, a wavelength demonstrating maximal difference between folded 
and unfolded spectra).  
The CD spectra at 222 nm at pH 4.5 show NEU1 and cathepsin A are folded at 
20ºC and are completely denatured at 85ºC with a transition at 47ºC and 59ºC, 
respectively (Figure 4.5 left column). When incubated together a single transition is 
observed at 52ºC, suggesting a co-operative unfolding. Cathepsin A also undergoes a 
similar unfolding at pH 7.0 with a Tm of 57ºC.  However, at pH 7 NEU1 exhibits an 
unusual temperature-dependent spectral change in the 85ºC denatured spectrum, 
having a larger CD signal than folded protein (20ºC), with a transition at 45ºC. When 
NEU1 and cathepsin A are incubated together changes in spectrum are only observed 
beyond 225 nm with a Tm of 74ºC. This >15ºC increase in the thermal melting point of 
the complex suggests increased stability of the complex (Figure 4.5 right column). 
Cooperative unfolding and stabilization of the complex is observed in the fraction-
denatured to temperature plots. 
4.4 Discussion 
Lysosomal neuraminidase is the only neuraminidase known to require binding 
partners for stability and activity in cells. NEU1 is a component of the lysosomal multi-
enzyme complex along with cathepsin A and β-galactosidase, and complex formation is 
proposed to activate NEU1 in the lysosome. Our pull down and SPR experiments show 
that NEU1 interacts with cathepsin A and forms a binary complex. Contrary to literature 
reports, we show that NEU1 does not depend on cathepsin A for catalysis, instead it 
may be stabilized by the interaction. 
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We made a homology model of NEU1 (Figure 4.6 a) and hypothesize it to form a 
6-bladed beta-propeller fold similar to NEU2 (human cytosolic neuraminidase, 28% 
sequence identity) and other bacterial neuraminidases (28 to 34% sequence identity). 
The top surface of the beta-propeller fold (ring) consists of loops that define the active 
site and substrate binding. The bottom surface is composed of loops containing the four 
Asp-box motifs, important for stability of beta-propeller proteins. The N- and C-termini of 
NEU1 are also near the bottom surface, away from the active site. Disease-causing 
mutations in NEU1 mapped onto a homology model have been used to gain insight into 
the binding interface on NEU1 for cathepsin A in the absence of any structural data for 
the complex (Figure 4.6 a). The region surrounding the residues F260, L270 and A298 
on NEU1 was proposed as the binding interface for cathepsin A based on stability 
studies on eight sialidosis mutants expressed in COS7 cells [107]. Our 
immunoprecipitation and biochemical pull down experiments suggest the interface may 
be at the C-terminus of NEU1, which is close to the residues L270 and A298 on the 
bottom surface of NEU1. Our data do not support the hypothesis of a cathepsin A 
binding site near F260, on the opposite surface of NEU1 closer to the active site (Figure 
4.6 b). A second study involving Surface Plasmon Resonance (SPR)-peptide screening 
of NEU1 (72 NEU1 15-mer peptides, with 10 amino acid overlap) demonstrated multiple 
potential cathepsin A binding sites [57]. Two alternate modes of NEU1 binding to 
cathepsin A were proposed based on binding profiles of those seven peptides (Figure 
4.6 c,d), which are spread out on all sides of the model. Only one of the peptides 
(binding model 1) near the C-terminus of NEU1 may support our experimental 
observations. However, all the other peptides are on the opposite surface or are part of 
β-stands (binding model 2). None of the peptides were tested for binding against a 
known non-interacting protein as a control, increasing the possibility of generating false 
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Figure 4.6: Proposed binding interfaces on NEU1 
(a) Homology model of NEU1 (grey) shows the residues involved in catalysis and 
substrate binding (side chains colored by atom, based on known structures of other 
neuraminidases) on the top surface and the loops containing the four Asp-box motifs on 
the bottom surface of the beta-propeller fold. The C-terminal eight residues are indicated 
in brown. (b) The three residues hypothesized to be involved in binding to cathepsin A. 
(c) and (d) Binding interfaces predicted based on the SPR-peptide screening, interface-1 
in green and interface-2 in blue, are spread out in the NEU1 model. 
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positives in the SPR-peptide screen. The binding interface may more specifically be 
determined with the knowledge gained from the work presented here. 
Complex formation in the lysosome is proposed to activate NEU1 by inducing 
conformational changes. Increase in specific activity of purified NEU1 
(1.8 µMol hr-1 mg-1) upon addition of cathepsin A (3.8 µMol hr-1 mg-1) at pH 6.5 and 5.0 
was inferred as cathepsin A induced activation of NEU1 [57]. Our enzymatic assay 
demonstrates the ability of NEU1 to bind and turn over substrate with a kcat of 2.14 min-1 
(specific activity 12.8x103 µMol hr-1 mg-1), which is a 1000-fold higher than the reported 
value for activated NEU1 [Chapter 3]. Additionally, no further substantial increase in 
activity is observed upon incubation with increasing concentrations of cathepsin A. A 
20% increase in activity was the maximum increase observed at a 1:1 ratio of NEU1 to 
cathepsin A, which decreased to no change in activity at a 1:8 ratio. It is possible that 
higher concentrations of cathepsin A in the 1:8 ratio resulted in some degradation of 
NEU1 in the two-hour time frame of the activity assay, although the experiments were 
carried out in the presence of benzamidine (a cathepsin A inhibitor). A recent study 
demonstrated that overexpression of NEU1 in NEU1-null fibroblasts led to correct 
lysosomal localization and activity of NEU1 even in the absence of cathepsin A co-
transfection [96]. These results support our data that show NEU1 is active in the 
absence of cathepsin A and does not depend on complex formation for catalytic 
activation.  
An increase in NEU1 protein level is observed in mammalian cells when NEU1 is 
expressed in the presence of the proteasome inhibitor MG132, suggesting NEU1 is 
unstable in the endoplasmic reticulum (ER) and is degraded by the ER associated 
degradation machinery (ERAD) [Chapter 3] [96]. Thermal stability (Tm) of NEU1 and 
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cathepsin A was determined by monitoring molar ellipticity at increasing temperatures 
using circular dichroism (CD). NEU1 exhibits an unusual change in the CD signal with 
increasing temperature at pH 7. This could be the result of formation of higher order 
beta-sheets or oligomers, as seen in some beta-sheet rich proteins [108]. At pH 7 the Tm 
of the complex is higher than that of the individual proteins and the fraction denatured 
plot shows a single transition, suggesting co-operative unfolding and increased stability 
of the complex compared to the individual proteins. Although a single transition is 
observed at pH 4.5, the Tm of the complex is nearly an average of the individual proteins. 
This could be due to differences in the nature of the NEU1-CATA interaction at the 
different pH conditions. The multi-enzyme complex is hypothesized to form in the ER 
and remain bound in the lysosome [57]. However, it is not clear how long the complex 
remains intact in the lysosome since some of the enzymes (cathepsin A and GLB1) 
require further processing for full enzymatic activity. Based on our data, we hypothesize 
that complex formation stabilizes the proteins in the ER, prevents degradation by ERAD, 
and results in proper trafficking to the lysosome. 
4.5 Methods 
4.5.1 Molecular Biology 
The cDNA for NEU1 and cathepsin A were purchased from Open Bio Systems 
and Harvard Institute of Proteomics, DNA Resource Core respectively. NEU1 constructs 
for insect cell and mammalian cell expression were generated as described in Chapter 3. 
Cathepsin A constructs were generated as described in Chapter 2. 
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4.5.2 Immunoprecipitation 
Plasmid expressing cathepsin A (with a C-terminal FLAG epitope) was 
cotransfected with plasmid expressing tagged or untagged version of NEU1 in 
HEK293T. Cells were harvested forty-eight hours post transfection and lysed using cold 
lysis buffer containing EDTA and protease inhibitor cocktail. Whole cell lysates were 
incubated with anti-FLAG M2 magnetic beads (Sigma Aldrich) for one hour at 4ºC. The 
beads were washed with Tris-buffered saline (TBS, 50 mM Tris-Cl, pH 7.5, 150 mM 
NaCl) buffer twice and bound proteins eluted by boiling with SDS loading buffer. 
Samples were analyzed for NEU1 and cathepsin A by western blot using anti-NEU1 and 
anti-cathepsin A antibodies (Rockland Immunochemicals).  
4.5.3 Surface Plasmon Resonance 
NEU1 (His6-TEV-NEU1) and cathepsin A (CATA-His6) were expressed and 
purified from insect cells (Tn5) as described in Chapters 3 and 2, respectively. Binding 
studies were performed on a Biacore 3000 instrument (GE Healthcare) using a CM5 
chip. Purified cathepsin A was immobilized to the CM5 chip in 10 mM sodium acetate 
buffer pH 4.5 by amine coupling (using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS)), followed by 1.0 M 
ethanolamine-HCl to block any residual reactive sites. Binding of NEU1 to cathepsin A 
was measured by flowing different concentrations of NEU1 in 50 mM acetate (running 
buffer) simultaneously through all four flow cells, double referenced by subtracting 
sensorgrams from flow-cell 1 and buffer. NEU1 was injected for 150 seconds at 
20 µL/min in running buffer, followed by regeneration in running buffer for 5 mins after 
each injection. A non-lysosomal protein (Nickel superoxide dismutase, NiSOD) used as 
a negative control did not show any binding event in the sensorgram. The flow cells were 
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maintained at 25ºC throughout the experiment. The corrected sensorgrams were 
analyzed using the Biacore software.  
4.5.4 Neuraminidase assay 
Exosialidase activity of NEU1 was measured using the synthetic substrate 2-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-MU-NANA, Gold Biotechnology) by 
monitoring the fluorescence of the released 4-MU (excitation at 365nm and emission at 
450 nm). Measurements were taken on a Spectra Max5 plate reader every 2 minutes for 
30 minutes. The amount of cleaved 4-MU was measured by comparing the fluorescence 
emission at 450 nm to a 4-MU standard curve. To test neuraminidase activity in the 
presence of cathepsin A, NEU1 was incubated with increasing molar concentrations of 
cathepsin A for 1 hour before performing the assay with 4-MU-NANA. Error bars were 
generated for all activity assays from triplicates.  
4.5.5 Thermal stability by circular dichroism 
Thermal stability of NEU1, cathepsin A and the complex was measured by 
circular dichroism (Jasco J715 spectropolarimeter) at different temperatures (18 – 90ºC, 
2º increments). Spectra were determined at pH 7 (20 mM phosphate and 125 mM NaCl) 
and pH 5 (20 mM sodium acetate, 125 mM NaCl). For spectra of individual proteins 
NEU1 and cathepsin A were diluted to a final concentration of 4 µM in the corresponding 
pH buffer (except cathepsin A at pH 5, 7 µM) and incubated for two hours at 4ºC. CD 
spectra (200 – 250 nm) at different temperatures were collected at a scan rate of 
20 nm/min using a 0.1 cm quartz cuvette on a Jasco 715 spectropolarimeter connected 
to a PTC-348WI temperature controller. For the complex, NEU1 and cathepsin A (4 µM 
of each) were incubated in corresponding buffer for two hours before collecting the 
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spectra. The molar ellipticity for the temperature-wavelength scans was calculated using 
the equation: 
 (1) 
where ΘMRE is the molar residual ellipticity, C is the protein concentration in mM, n is the 
number of amino acids per monomer (368 for NEU1, 452 for cathepsin A, 820 for 
complex), MW is the molecular weight of the protein sample (40236 Da for NEU1, 51409 
Da for cathepsin A and 91645 Da for the complex) and l is the path length of the cell, 0.1 
cm. The units are in deg.cm2/dmol/res. The fraction denatured, Fd was calculated from 
the molar ellipticity data, at 222 nm for pH 5 and 230 nm for pH 7, using: 
  (2) 
where Θobs is the calculated molar ellipticity and ΘN and ΘU are the molar ellipticity 
corresponding to the native or folded (20 ºC) and non-native or unfolded (85 ºC) states 
respectively. The Tm was determined as the temperature at which half the protein is 
denatured (Fd = ). 
4.5.6 Homology modeling 
A homology model of NEU1 was built based on the structures of homologous 
human and bacterial neuraminidases, including Micromonospora virifaciens (PDB: 
1EUT, 30% identity), human neuraminidase 2 (PDB: 1SNT, 28% identity), Streptococcus 
pneumoniae (PDB: 3H72) and Clostridium perfrengens (PDB: 2BF6). The domain 
insertion present in the neuraminidases of S. pneumoniae (residues 127-221) and C 
perfrengens (residues 111-190) were not considered for the structure-based sequence 
alignment. The sequence identity for the segments N-terminal and C-terminal to the 
€ 
ΘMRE =
CDsignal × MW
C × n × l
€ 
Fd =
ΘN −Θobs
ΘN −ΘU
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insertion is 34% and 28% respectively. The Swiss PDB Viewer program [109] was used 
to generate a NEU1 model based on structure-based sequence alignment. Gaps and 
insertions in the NEU1 model were built in O using the lego-loop tool [110].  
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5       CHAPTER 5 
DISCUSSION 
 
The crystal structure of the active mature form of cathepsin A described in 
Chapter 2 clarifies the composition and activation mechanism of mature cathepsin A. 
Cathepsin A plays an important role in the homeostasis of cardiovascular and endocrine 
system, and inhibitors against cathepsin A are currently in clinical trials for hypertension 
and cardiac diseases [58]. Since there are no available treatments for patients with 
galactosialidosis, exploring pharmacological chaperone therapy with the cathepsin A 
inhibitors may provide new treatment options. Our structural studies on mature 
cathepsin A, in addition to a similar crystal structure published recently [111], will 
facilitate further design and optimization of molecules with specific properties. Although 
the potency of inhibitor binding to the precursor form of cathepsin A may not be optimal, 
binding to the mature form of the protein in the Golgi apparatus could promote 
stabilization of mutations causing milder forms of the disease (Figure 5.1).  
In Chapter 3 we introduced the concept of PCT targeting NEU1 for the treatment 
of sialidosis and galactosialidosis (Figure 5.1). The two inhibitors tested (neuraminic acid 
or NANA and 2,3-dehydro-2-deoxyneuraminic acid or DANA) stabilized wild type NEU1, 
in biochemical and cellular studies. Additionally, determining their effects on stability and 
lysosomal localization of mutant forms of NEU1 in future studies will reveal which 
genotypes are responsive to PCT. The inhibitors presented in this work are widely used 
as scaffolds for the development of potent inhibitors against viral and bacterial 
neuraminidases [112]. Modification of the hydroxyl at the C9 position was shown to 
generate inhibitors specific to NEU1, with improved affinity compared to NANA and 
DANA [101, 113]. These and other neuraminidase inhibitors (Zanamivir and Oseltamivir, 
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FDA approved drugs for treatment of influenza) are very good candidates for achieving 
better pharmacological chaperoning, and might be repurposed for sialidosis and 
galactosialidosis. Regulation of cell membrane expressed NEU1 activity for restricting 
cancer metastasis is currently being investigated with oseltamivir phosphate (Tamiflu). 
Any future pharmacological studies based on inhibition of NEU1 will have to consider the 
different effects of the inhibitors on NEU1 function in the lysosome and on the cell 
surface. Pharmacological chaperone studies targeting wild type NEU1 in 
galactosialidosis fibroblasts could pave the way for an alternate treatment option for 
galactosialidosis, as NEU1 activity does not require cathepsin A (Chapter 4). Effect of 
the inhibitors on the stability of different disease-causing mutants can be tested by in 
vitro and cellular studies, similar to those presented in Chapter 3. These studies will aid 
in the determination of responsive and non-responsive mutations in sialidosis and 
galactosialidosis, and will provide a reference point for evaluating treatment options in 
the future.  
In an attempt to understand the multi-enzyme complex we undertook a bottom-up 
approach by focusing on the two-protein complex of NEU1 and cathepsin A (Figure 5.2). 
In Chapter 4 we analyzed the NEU1-CATA complex and the effect of complex formation 
on NEU1 activity and stability. Contrary to literature reports, we show NEU1 is active in 
the absence of cathepsin A and β-galactosidase, with only a 20% increase in activity 
observed in a molar excess of cathepsin A. The NEU1 used in these assays was 
expressed and purified from insect cells with a cleavable N-terminal tag. Cleavage of the 
tag leaves two glycine residues at the N-terminus of mature NEU1 (after signal 
sequence cleavage), which are unlikely to affect the structure or activity of NEU1. 
Additionally, a C-terminal His6 tagged NEU1 construct exhibits a similar kinetic profile 
(chapter 3), suggesting the extra residues at the termini do not affect NEU1 activity. 
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Figure 5.1: Pharmacological chaperone therapy for galactosialidosis and 
sialidosis 
A pictorial representation of PCT for galactosialidosis and sialidosis using cathepsin A 
inhibitors and NEU1 (green hexagon and red star respectively) shows stabilization of 
proteins by inhibitor resulting in trafficking to lysosome. Inhibitors dissociate in high 
substrate concentrations of the lysosome leading to reduction in substrate accumulation. 
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In both cases the neuraminidase activity was lost due to protein precipitation when 
stored for more than two weeks at 4 ºC, suggesting reduced stability of the purified 
protein compared to immediately post purification. NEU1 expressed with a N- or C- 
terminal tag is more stable than the untagged version, providing a new strategy for the 
expression and purification of NEU1 for biochemical studies.  
We hypothesize that complex formation may stabilize NEU1 in cells, thereby 
affecting neuraminidase activity, as NEU1 was highly active in the absence of 
cathepsin A. The thermal denaturation experiments with NEU1 and cathepsin A suggest 
that complex formation is important for stability of the proteins, although the data 
presented here do not rule out other models. Additional techniques to assess stability of 
the complex and individual proteins, such as susceptibility to proteolysis [114] and dye-
based monitoring of protein folded state as a function of chemical or thermal 
denaturation [115] can provide more insight on this model.  
Binding studies with purified NEU1 and cathepsin A using surface plasmon 
resonance (SPR) shown in Chapter 4 confirms the NEU1-catA interaction, clarifying the 
inconclusive reports using both size exclusion chromatography [17] and analytical 
ultracentrifugation [57]. Preliminary SPR data show GLB1 binding to both cathepsin A 
and NEU1, suggesting the ternary complex is organized as a globular structure rather 
than beads on a string (data not shown). Further binding studies using SPR and other 
techniques will aid in understanding the organization of the complex and in elucidating 
the binding affinity for proteins in the complex. 
Many aspects of the multi-enzyme complex however are still not clearly 
understood. Firstly, NEU1 in the complex localizes to the cell membrane and is involved 
in various cellular processes by virtue of its sialidase activity. The pH profile of NEU1 
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Figure 5.2: Current knowledge of the complex and future directions 
The work presented in this thesis has clarified some of the many questions regarding the 
NEU1-cathepsin A complex (denoted by ). NEU1-cathepsin A interaction was 
confirmed, and this complex formation is important for stability of the proteins. NEU1 
activity in the presence and absence of cathepsin A are similar (≈). Processes denoted 
by question marks identify some of the important aspects of the complex that need to be 
addressed. 
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activity in vitro (against a synthetic substrate) shows negligible activity above pH 6.5, 
which does not explain the NEU1 dependent neuraminidase activity observed in the 
neutral pH of the extracellular matrix. The reduced activity at neutral pH in our assay 
could be due to changes in affinity of the substrate, which may be different for natural 
substrates present in the extracellular matrix. Kinetic analysis at different pH conditions 
and substrates can provide further insight into this. Secondly, different studies using 
proteins (including GLB1, NEU1 and catA) purified from tissue homogenates and 
heterogeneous expression have proposed complexes with varying composition, 
molecular weight, stoichiometric ratios and pH dependent association and dissociation. 
Cellular and biochemical analyses using a systematic top-down or bottom-up (as used in 
Chapter 4) approach will aid in understanding the complex. Techniques such as 
fluorescence imaging using specific fluorescent tags or labels for each component (not 
antibody mediated) can be used to study oligomerization and trafficking in cells. To this 
end, addition of a C-terminal GFP to cathepsin A has been shown not to interfere with 
protein function or trafficking [116]. High-resolution or low-resolution (small-angle X-ray 
scattering) structural data for the three-protein or two-protein complexes will provide 
valuable information regarding binding interfaces and protein organization in the 
complex. Thirdly, the trafficking mechanism for NEU1 is debated, with one line of 
evidence pointing towards a cathepsin A mediated transport [16], while a second points 
towards trafficking via an alternate receptor or C-terminal YGTL internalization motif 
(YXXΦ consensus sequence) mediated transport [117]. Identification of alternate 
receptors will support the second model for trafficking and help in the exploration of PCT 
targeting NEU1 without cathepsin A involvement.  
The proteins involved in the lysosomal multi-enzyme complex: cathepsin A, 
NEU1, GLB1 and GALNS are ubiquitously expressed. The different diseases associated 
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with deficiencies in these proteins highlight their functional importance for catabolism in 
the lysosome and different cellular processes. A thorough knowledge of the functional 
interdependencies of these proteins is thus essential for understanding the molecular 
bases of the corresponding storage diseases and for the development of therapeutics. 
Currently, very little about the complex is understood, and the work presented in this 
thesis will aid in future analyses of the complex. The approaches used for the 
characterization of the NEU1-CATA complex presented here can be utilized for the 
characterization of the four-protein complex.  
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